Eligible	B-P	ADJ	O
patients	I-P	NOUN	B
will	I-P	AUX	O
present	I-P	VERB	O
AF	I-P	NOUN	B
lasting	I-P	VERB	O
less	I-P	ADJ	O
than	I-P	ADP	O
43	I-P	NUM	O
hours	I-P	NOUN	B
,	I-P	PUNCT	O
will	I-P	AUX	O
be	I-P	AUX	O
in	I-P	ADP	O
stable	I-P	ADJ	B
cardio-pulmonary	I-P	ADJ	B
condition	I-P	NOUN	I
and	I-P	CCONJ	O
will	I-P	AUX	O
have	I-P	AUX	O
no	I-P	DET	O
prior	I-P	ADJ	O
history	I-P	NOUN	O
of	I-P	ADP	O
advanced	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
or	I-P	CCONJ	O
significant	I-P	ADJ	O
valvular	I-P	ADJ	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Cementing	O	NOUN	B
technique	O	NOUN	I
is	O	AUX	O
a	O	DET	O
crucial	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
prosthesis	B-P	NOUN	B
fixation	I-P	NOUN	B
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
We	O	PRON	O
randomized	O	VERB	B
50	B-P	NUM	O
THAs	I-I	NOUN	B
to	I-I	PART	O
either	I-I	CCONJ	O
fingerpacking	I-I	NOUN	B
or	I-I	CCONJ	O
sequential	I-I	ADJ	B
pressurization	I-I	NOUN	B
(	I-I	PUNCT	O
including	I-I	VERB	O
individual	I-I	ADJ	O
pressurization	I-I	NOUN	B
of	I-I	ADP	O
each	I-I	DET	O
anchorage	I-I	NOUN	B
hole	I-I	NOUN	I
)	I-I	PUNCT	O
and	I-P	CCONJ	O
followed	I-P	VERB	O
the	I-P	DET	O
patients	I-P	NOUN	B
with	I-P	ADP	O
RSA	I-I	NOUN	B
for	I-P	ADP	O
5	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
adult	B-I	ADJ	B
intervention	I-I	NOUN	B
on	O	ADP	O
infants	B-OUT	NOUN	B
'	I-OUT	PART	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
attention	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Level	O	NOUN	B
of	O	ADP	O
intervention	O	NOUN	B
was	O	AUX	O
controlled	O	VERB	B
by	O	ADP	O
systematically	B-I	ADV	B
varying	I-I	VERB	O
the	I-I	DET	O
manner	I-I	NOUN	O
and	I-I	CCONJ	O
frequency	I-I	NOUN	B
with	I-I	ADP	O
which	I-I	DET	O
objects	I-I	NOUN	B
were	I-I	AUX	O
presented	I-I	VERB	O
,	I-I	PUNCT	O
the	I-I	DET	O
extent	I-I	NOUN	O
to	I-I	PART	O
which	I-I	DET	O
the	I-I	DET	O
experimenter	I-I	NOUN	B
talked	I-I	VERB	O
to	I-I	ADP	O
the	I-I	DET	O
infant	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
physical	I-I	ADJ	B
proximity	I-I	NOUN	I
.	I-I	PUNCT	O


Infant	O	ADJ	B
attention	O	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
time	I-OUT	NOUN	O
spent	I-OUT	VERB	O
examining	I-OUT	VERB	O
objects	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
level	O	NOUN	B
of	O	ADP	O
intervention	B-I	NOUN	B
interacts	O	VERB	O
with	O	ADP	O
the	O	DET	O
child	B-OUT	NOUN	B
's	I-OUT	PART	I
spontaneous	I-OUT	ADJ	B
tendency	I-OUT	NOUN	O
to	I-OUT	PART	O
focus	I-OUT	VERB	O
attention	I-OUT	NOUN	O
on	O	ADP	O
objects	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
recently	O	ADV	O
demonstrated	O	VERB	O
that	O	SCONJ	O
continuous	B-I	ADJ	O
positive	I-I	ADJ	B
airway	I-I	NOUN	O
pressure	I-I	NOUN	O
(	I-P	PUNCT	O
CPAP	I-P	NOUN	B
)	I-P	PUNCT	O
effectively	I-P	ADV	O
decreases	I-P	VERB	B
respiratory	I-OUT	ADJ	B
rate	I-OUT	NOUN	I
in	I-P	ADP	O
children	I-P	NOUN	B
presenting	I-P	VERB	O
to	I-P	ADP	O
Ghanaian	I-P	ADJ	B
district	I-P	NOUN	B
hospitals	I-P	NOUN	B
with	I-P	ADP	O
respiratory	I-P	ADJ	B
distress	I-P	NOUN	I
.	I-P	PUNCT	O


Twenty-eight	B-P	NUM	B
nurses	I-P	NOUN	I
participated	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
,	I-P	PUNCT	O
9	I-P	NUM	O
first-generation	I-P	NOUN	B
and	I-P	CCONJ	O
19	I-P	NUM	O
second-generation	I-P	NOUN	B
.	I-P	PUNCT	O


First-generation	O	ADJ	B
trainees	O	NOUN	I
scored	O	VERB	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
second-generation	O	ADJ	B
trainees	O	NOUN	I
on	O	ADP	O
both	O	DET	O
skills	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
knowledge	I-OUT	NOUN	B
assessments	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Transient	O	ADJ	B
or	O	CCONJ	O
final	O	ADJ	O
side	O	NOUN	O
branch	O	NOUN	O
occlusion	O	NOUN	O
occurred	O	VERB	O
less	O	ADV	O
frequently	O	ADV	O
in	O	ADP	O
patients	B-P	NOUN	B
receiving	I-P	VERB	O
EES	I-P	NOUN	B
compared	I-P	VERB	O
to	I-P	ADP	O
PES	I-P	NOUN	B
(	O	PUNCT	O
2.8	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
5.2	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p=0.009	O	PROPN	O
)	O	PUNCT	O
,	O	PUNCT	O
contributing	O	VERB	O
to	O	PART	O
the	O	DET	O
numerically	O	ADV	B
lower	O	ADJ	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
in-hospital	I-OUT	ADJ	B
NQMI	I-OUT	NOUN	O
with	O	ADP	O
EES	O	NOUN	B
arm	O	NOUN	B
compared	O	VERB	B
to	O	ADP	O
PES	O	NOUN	B
(	O	PUNCT	O
0.7	O	NUM	O
%	O	NOUN	O
vs.	O	CCONJ	O
2.3	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
p=0.05	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
providers	B-P	NOUN	B
'	I-P	PART	O
in-office	I-P	NOUN	B
use	I-P	NOUN	O
of	I-P	ADP	O
CDC	I-P	PROPN	B
gynecologic	I-P	ADJ	B
cancer	I-P	NOUN	I
materials	I-P	NOUN	O
and	I-P	CCONJ	O
their	I-P	PRON	O
recognition	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
symptoms	I-P	NOUN	B
highlighted	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
materials	I-P	NOUN	B
.	I-P	PUNCT	O


Distributing	O	VERB	O
consumer	O	NOUN	B
education	O	NOUN	I
materials	O	NOUN	I
in	O	ADP	O
health	O	NOUN	B
care	O	NOUN	I
provider	O	NOUN	I
offices	O	NOUN	O
remains	O	VERB	O
a	O	DET	O
priority	O	NOUN	B
for	O	ADP	O
the	O	DET	O
Inside	O	PROPN	O
Knowledge	O	PROPN	B
campaign	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
where	O	SCONJ	O
women	O	NOUN	B
and	B-P	CCONJ	O
health	I-P	NOUN	B
care	I-P	NOUN	I
providers	I-P	NOUN	I
interact	O	VERB	B
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
most	O	ADV	O
crucial	O	ADJ	O
venues	O	NOUN	B
to	O	PART	O
promote	O	VERB	B
awareness	O	NOUN	B
of	O	ADP	O
gynecologic	O	ADJ	B
cancer	O	NOUN	I
symptoms	O	NOUN	B
.	O	PUNCT	O


Efficacy	O	NOUN	B
of	O	ADP	O
omeprazole	B-I	NOUN	B
versus	O	CCONJ	O
high-dose	B-I	ADJ	B
famotidine	I-I	NOUN	B
for	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
exercise-induced	B-OUT	ADJ	B
gastritis	I-OUT	NOUN	I
in	O	ADP	O
racing	B-P	VERB	B
Alaskan	I-P	ADJ	B
sled	I-P	NOUN	I
dogs	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
Omeprazole	B-I	NOUN	B
and	O	CCONJ	O
famotidine	B-I	NOUN	B
both	O	DET	O
reduce	O	VERB	B
severity	O	NOUN	B
of	O	ADP	O
exercise-induced	B-OUT	ADJ	B
gastritis	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
administering	O	VERB	B
famotidine	O	NOUN	B
is	O	AUX	O
easier	O	ADJ	O
than	O	ADP	O
administering	O	VERB	B
omeprazole	O	NOUN	B
during	O	ADP	O
racing	O	NOUN	B
competition	O	NOUN	I
.	O	PUNCT	O


ANIMALS	O	NOUN	B
Experiment	O	PROPN	B
1	O	NUM	O
:	O	PUNCT	O
Randomized	B-P	ADJ	B
placebo-controlled	I-P	ADJ	I
study	I-P	NOUN	I
,	I-P	PUNCT	O
36	I-P	NUM	O
sled	I-P	NOUN	B
dogs	I-P	NOUN	I
(	I-P	PUNCT	O
3-8	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
;	I-P	PUNCT	O
Experiment	O	NOUN	B
2	O	NUM	O
:	O	PUNCT	O
Randomized	B-P	ADJ	B
positive-control	I-P	ADJ	O
study	I-P	NOUN	O
,	I-P	PUNCT	O
52	I-P	NUM	O
sled	I-P	NOUN	B
dogs	I-P	NOUN	I
(	I-P	PUNCT	O
2-8	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Mucosal	B-OUT	ADJ	B
appearance	I-OUT	NOUN	B
was	O	AUX	O
blindly	O	ADV	B
scored	O	VERB	B
by	O	ADP	O
previously	O	ADV	O
described	O	VERB	O
scoring	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


Experiment	O	NOUN	B
2	O	NUM	O
:	O	PUNCT	O
Equal	O	ADJ	B
numbers	O	NOUN	O
of	O	ADP	O
dogs	O	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
omeprazole	B-I	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
q24h	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
high-dose	O	ADJ	B
famotidine	B-I	NOUN	B
(	O	PUNCT	O
40	O	NUM	O
mg	O	NOUN	O
q12h	O	NOUN	B
)	O	PUNCT	O
groups	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
Famotidine	B-I	NOUN	B
reduced	O	VERB	B
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
clinically	B-OUT	ADV	B
relevant	I-OUT	ADJ	I
,	I-OUT	PUNCT	O
exercise-induced	I-OUT	ADJ	B
gastric	I-OUT	ADJ	I
lesions	I-OUT	NOUN	I
compared	O	VERB	O
with	O	ADP	O
no	O	DET	B
treatment	O	NOUN	I
(	O	PUNCT	O
7/16	O	NUM	O
versus	O	CCONJ	O
11/16	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.031	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-OUT	ADJ	B
heartburn	I-OUT	NOUN	I
but	I-P	CCONJ	O
with	I-P	ADP	O
no	I-P	DET	O
endoscopic	I-P	ADJ	B
evidence	I-P	NOUN	B
of	I-P	ADP	O
erosive	I-P	ADJ	B
oesophagitis	I-P	NOUN	I
require	I-P	VERB	O
gastric	I-P	ADJ	B
acid	I-P	NOUN	I
suppression	I-P	NOUN	B
to	I-P	PART	O
relieve	I-OUT	VERB	O
symptoms	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	VERB	O
Two	O	NUM	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
4-week	O	NOUN	B
,	O	PUNCT	O
multi-centre	O	ADJ	B
trials	O	NOUN	I
with	O	ADP	O
identical	O	ADJ	B
methodology	O	NOUN	B
compared	O	VERB	O
once-daily	O	ADJ	B
esomeprazole	B-I	NOUN	B
,	O	PUNCT	O
40	B-P	NUM	O
mg	I-P	NOUN	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
241	I-P	NUM	O
)	I-P	PUNCT	O
or	I-P	CCONJ	O
20	I-P	NUM	O
mg	I-P	NOUN	O
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
234	I-P	NUM	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
with	I-P	ADP	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
242	I-P	NUM	O
)	I-P	PUNCT	O
for	O	ADP	O
the	O	DET	O
rigorous	O	ADJ	O
end-point	O	NOUN	B
of	O	ADP	O
complete	B-OUT	ADJ	B
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Secondary	O	ADJ	B
end-points	O	NOUN	B
included	O	VERB	O
the	O	DET	O
percentage	B-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn-free	I-OUT	ADJ	B
days	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
time	I-OUT	NOUN	O
to	I-OUT	ADP	O
first	I-OUT	ADV	O
and	I-OUT	CCONJ	O
sustained	I-OUT	ADJ	B
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
either	O	CCONJ	O
dose	O	NOUN	B
of	O	ADP	O
esomeprazole	B-I	NOUN	B
were	O	AUX	O
two	O	NUM	O
to	O	PART	O
three	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
achieve	O	VERB	O
complete	B-OUT	ADJ	O
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn	I-OUT	NOUN	B
than	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
placebo	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
is	O	AUX	O
growing	O	VERB	O
evidence	O	NOUN	B
of	O	ADP	O
an	O	DET	O
association	O	NOUN	B
between	O	ADP	O
physical	O	ADJ	B
illness	O	NOUN	I
and	O	CCONJ	O
problem	O	NOUN	B
behavior	O	NOUN	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
developmental	I-P	ADJ	B
disabilities	I-P	NOUN	B
.	I-P	PUNCT	O


Following	O	VERB	O
intervention	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
behavioral	O	ADJ	B
plus	O	CCONJ	O
medical	O	ADJ	B
intervention	O	NOUN	I
group	O	NOUN	I
showed	O	VERB	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
problem	B-OUT	NOUN	B
behavior	I-OUT	NOUN	I
and	O	CCONJ	O
completed	B-OUT	VERB	O
more	I-OUT	ADV	O
academic	I-OUT	ADJ	B
tasks	I-OUT	NOUN	O
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
medical	O	ADJ	B
intervention	O	NOUN	I
alone	O	ADJ	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
concept	B-OUT	NOUN	B
of	I-OUT	ADP	O
illness	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
as	O	ADP	O
a	O	DET	O
setting	O	NOUN	O
event	O	NOUN	B
for	O	ADP	O
problem	O	NOUN	B
behavior	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
need	O	NOUN	O
for	O	ADP	O
research	O	NOUN	B
to	O	PART	O
develop	O	VERB	O
algorithms	O	NOUN	B
that	O	PRON	O
allow	O	VERB	O
one	O	NUM	O
to	O	PART	O
select	O	VERB	O
the	O	DET	O
best	O	ADJ	O
combination	O	NOUN	B
of	O	ADP	O
medical	B-I	ADJ	B
and	I-I	CCONJ	O
behavioral	I-I	ADJ	B
interventions	I-I	NOUN	B
for	O	ADP	O
specific	O	ADJ	O
illnesses	O	NOUN	B
and	O	CCONJ	O
contexts	O	NOUN	B
is	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


An	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
chemical	O	ADJ	B
arthrodesis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
proximal	B-P	ADJ	B
interphalangeal	I-P	NOUN	I
joint	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
horse	I-P	NOUN	B
by	O	ADP	O
using	O	VERB	O
monoiodoacetate	B-I	NOUN	B
.	I-I	PUNCT	O


Eight	B-P	NUM	O
horses	I-P	NOUN	B
received	O	VERB	O
3	O	NUM	O
injections	O	NOUN	B
(	O	PUNCT	O
Weeks	O	PROPN	B
0	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
MIA	B-I	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mL	O	NOUN	O
;	O	PUNCT	O
60	O	NUM	O
mg/mL	O	NOUN	O
)	O	PUNCT	O
into	O	ADP	O
the	O	DET	O
right	O	ADJ	B
or	O	CCONJ	O
left	O	ADJ	B
front	O	ADJ	I
PIJ	O	PROPN	B
.	O	PUNCT	O


Peri-operatively	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
horses	O	NOUN	B
received	O	VERB	O
phenylbutazone	B-I	NOUN	B
,	I-I	PUNCT	O
butorphanol	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
abaxial	I-I	ADJ	B
sesamoidean	I-I	ADJ	I
nerve	I-I	NOUN	I
blocks	I-I	NOUN	B
to	O	PART	O
relieve	O	VERB	O
pain	O	NOUN	B
.	O	PUNCT	O


Exercise	B-I	NOUN	B
consisted	O	VERB	O
of	O	ADP	O
20	O	NUM	O
minutes	O	NOUN	B
of	O	ADP	O
trotting	O	NOUN	B
on	O	ADP	O
a	O	DET	O
treadmill	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
m/s	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
3	O	NUM	O
days	O	NOUN	B
per	O	ADP	O
week	O	NOUN	B
for	O	ADP	O
13	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Histologic	B-OUT	ADJ	B
examination	I-OUT	NOUN	I
revealed	I-OUT	VERB	O
thinning	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
cartilage	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
diffuse	I-OUT	ADJ	B
necrosis	I-OUT	NOUN	B
of	I-OUT	ADP	O
chondrocytes	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
with	I-OUT	ADP	O
the	I-OUT	DET	O
calcified	I-OUT	VERB	B
zone	I-OUT	NOUN	I
intact	I-OUT	ADJ	B
.	I-OUT	PUNCT	O


Subjectively	B-OUT	ADV	B
,	I-OUT	PUNCT	O
exercise	I-OUT	NOUN	B
did	I-OUT	AUX	O
not	I-OUT	PART	O
influence	I-OUT	VERB	B
the	I-OUT	DET	O
degree	I-OUT	NOUN	B
of	I-OUT	ADP	O
cartilage	I-OUT	NOUN	B
destruction	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


INTRODUCTION	O	PUNCT	O
Current	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
Social	B-I	PROPN	B
Stories	I-I	PROPN	I
can	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
tackling	O	VERB	O
problem	B-OUT	NOUN	B
behaviours	I-OUT	NOUN	I
exhibited	O	VERB	O
by	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Case	O	NOUN	B
reports	O	VERB	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
stories	O	NOUN	B
can	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
benefits	O	NOUN	B
including	O	VERB	O
improvements	O	NOUN	B
in	O	ADP	O
social	B-OUT	ADJ	B
interactions	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
choice	I-OUT	NOUN	O
making	I-OUT	VERB	O
in	O	ADP	O
educational	O	ADJ	B
settings	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
investigated	O	VERB	B
perceptual	B-OUT	ADJ	B
learning	I-OUT	NOUN	O
in	O	ADP	O
two	O	NUM	O
optimal	O	ADJ	B
conditions	O	NOUN	B
:	O	PUNCT	O
conversational	B-I	ADJ	B
speech	I-I	NOUN	I
(	I-I	PUNCT	O
Experiment	I-I	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
versus	O	CCONJ	O
clear	B-I	ADJ	B
speech	I-I	NOUN	I
(	O	PUNCT	O
Experiment	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
adverse	O	ADJ	B
conditions	O	NOUN	I
:	O	PUNCT	O
noise	B-I	NOUN	B
(	O	PUNCT	O
Experiment	O	NOUN	B
3a	O	NOUN	I
)	O	PUNCT	O
versus	O	CCONJ	O
two	B-I	NUM	O
cognitive	I-I	ADJ	B
loads	I-I	NOUN	I
(	O	PUNCT	O
Experiments	O	NOUN	B
4a	O	NOUN	I
and	O	CCONJ	O
4b	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Perceptual	B-OUT	ADJ	B
learning	I-OUT	NOUN	O
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
optimal	B-I	ADJ	B
conditions	I-I	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
cognitive	B-I	ADJ	B
load	I-I	NOUN	I
conditions	I-I	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
the	O	DET	O
noise	B-I	NOUN	B
condition	I-I	NOUN	I
.	I-I	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
perceptual	B-OUT	ADJ	B
learning	I-OUT	NOUN	O
occurred	O	VERB	O
only	O	ADV	O
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
of	O	ADP	O
two	O	NUM	O
sessions	O	NOUN	B
for	O	ADP	O
each	O	DET	O
participant	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
only	O	ADV	O
for	O	ADP	O
atypical	O	ADJ	B
/s/	O	ADJ	O
sounds	O	NOUN	B
and	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
atypical	O	ADJ	B
/f/	O	PUNCT	O
sounds	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
experimental	B-P	ADJ	B
group	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
80	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
instructed	O	VERB	O
to	O	PART	O
gargle	B-I	VERB	B
6	I-I	NUM	O
times	I-I	NOUN	O
daily	I-I	ADV	O
with	I-I	ADP	O
warm	I-I	ADJ	B
saline	I-I	NOUN	I
and	O	CCONJ	O
no	B-I	DET	O
such	I-I	ADJ	O
instructions	I-I	NOUN	B
were	O	AUX	O
given	O	VERB	O
to	O	ADP	O
the	O	DET	O
second	B-P	ADJ	O
group	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
80	I-P	NUM	O
)	I-P	PUNCT	O
to	O	PART	O
serve	O	VERB	O
as	O	ADP	O
controls	B-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
statistical	O	ADJ	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
study	O	NOUN	B
groups	O	NOUN	I
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
development	O	NOUN	B
of	O	ADP	O
alveolar	B-OUT	ADJ	B
osteitis	I-OUT	NOUN	I
(	O	PUNCT	O
X2	O	NOUN	O
=	O	ADJ	O
15.00	O	NUM	O
,	O	PUNCT	O
df	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
,	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.The	O	PUNCT	O
risk	B-OUT	NOUN	B
of	I-OUT	ADP	O
development	I-OUT	NOUN	B
of	I-OUT	ADP	O
alveolar	I-OUT	ADJ	B
osteitis	I-OUT	NOUN	I
was	O	AUX	O
4	O	NUM	O
times	O	NOUN	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
OR	O	NOUN	B
=	O	ADJ	O
4.33	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Warm	B-I	ADJ	B
saline	I-I	NOUN	I
mouth	I-I	NOUN	I
rinse	I-I	NOUN	B
instruction	O	NOUN	B
is	O	AUX	O
beneficial	O	ADJ	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
alveolar	B-OUT	ADJ	B
osteitis	I-OUT	NOUN	I
after	O	ADP	O
dental	O	NOUN	B
extractions	O	NOUN	I
.	O	PUNCT	O


Subjects/Study	O	NOUN	B
interventions	O	NOUN	I
:	O	PUNCT	O
Forty-one	B-P	NUM	O
(	I-P	PUNCT	O
41	I-P	NUM	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
were	I-P	AUX	O
studied	I-P	VERB	O
.	I-P	PUNCT	O


Patients	O	NOUN	B
received	O	VERB	O
single-needle	B-I	ADJ	B
acupuncture	I-I	NOUN	I
with	O	ADP	O
a	O	DET	O
0.2	O	NUM	O
x	O	NOUN	O
13	O	NUM	O
mm	O	NOUN	O
disposable	O	ADJ	B
acupuncture	O	NOUN	I
needle	O	NOUN	I
(	O	PUNCT	O
Suzhou	O	PROPN	B
Medical	O	PROPN	I
Appliances	O	PROPN	I
,	O	PUNCT	O
China	O	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
10-mm	O	ADJ	O
deep	O	ADJ	B
either	O	CCONJ	O
at	O	ADP	O
Chengjiang	O	PROPN	B
(	O	PUNCT	O
midline	O	NOUN	B
between	O	ADP	O
lower	O	ADJ	B
lip	O	NOUN	I
and	O	CCONJ	O
chin	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
superficially	O	ADV	B
at	O	ADP	O
a	O	DET	O
sham	O	NOUN	B
point	O	NOUN	O
(	O	PUNCT	O
tip	O	NOUN	O
of	O	ADP	O
the	O	DET	O
chin	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
TEE	O	NOUN	B
or	O	CCONJ	O
no	B-I	DET	O
acupuncture	I-I	NOUN	O
for	O	ADP	O
alleviating	O	VERB	O
gag	O	NOUN	B
reflex	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
acupuncture	O	NOUN	B
group	O	NOUN	I
experienced	O	VERB	O
significantly	O	ADV	O
less	B-OUT	ADV	O
gagging	I-OUT	ADJ	B
than	O	ADP	O
the	O	DET	O
sham	O	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.037	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
nonacupuncture	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.013	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Acupuncture	B-I	NOUN	B
of	I-I	ADP	O
CV24	I-I	PROPN	B
is	O	AUX	O
an	O	DET	O
easy	O	ADJ	O
to	O	PART	O
apply	O	VERB	O
and	O	CCONJ	O
effective	O	ADJ	B
method	O	NOUN	B
to	O	PART	O
reduce	O	VERB	O
gag	B-OUT	NOUN	B
reflex	I-OUT	NOUN	I
during	O	ADP	O
TEE	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
rigorous	O	ADJ	O
statistical	O	ADJ	B
method	O	NOUN	I
of	O	ADP	O
scale	O	NOUN	O
construction	O	NOUN	B
consisting	O	VERB	O
of	O	ADP	O
a	O	DET	O
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
scale	O	NOUN	B
discrimination	O	NOUN	I
technique	O	NOUN	I
was	O	AUX	O
employed	O	VERB	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
45-item	B-I	ADJ	B
questionnaire	I-I	NOUN	I
representing	O	VERB	O
three	O	NUM	O
orthogonally	O	ADV	O
derived	O	VERB	O
scales	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
second	O	ADJ	O
study	O	NOUN	B
of	O	ADP	O
predictive	O	ADJ	B
validity	O	NOUN	I
,	O	PUNCT	O
40	B-P	NUM	O
individuals	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
conditions	O	NOUN	B
:	O	PUNCT	O
relaxation	B-I	NOUN	B
training	I-I	NOUN	I
,	I-I	PUNCT	O
tension	I-I	NOUN	B
inducement	I-I	NOUN	B
,	I-I	PUNCT	O
pre-postcontrol	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
postcontrol	I-I	NOUN	B
.	I-I	PUNCT	O


Randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
secondhand	B-I	NOUN	B
smoke	I-I	NOUN	I
exposure	I-I	NOUN	B
reduction	I-I	NOUN	B
intervention	I-I	NOUN	B
among	O	ADP	O
hospital-based	B-P	ADJ	B
pregnant	I-P	ADJ	I
women	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
secondhand	B-I	NOUN	B
tobacco	I-I	NOUN	I
smoke	I-I	NOUN	I
(	I-I	PUNCT	O
SHS	I-I	NOUN	B
)	I-I	PUNCT	O
prevention	I-I	NOUN	B
program	I-I	NOUN	I
based	O	VERB	O
on	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
Health	B-OUT	PROPN	B
Belief	I-OUT	PROPN	I
Model	I-OUT	PROPN	I
(	O	PUNCT	O
HBM	O	PROPN	B
)	O	PUNCT	O
incorporating	O	VERB	O
self-efficacy	O	NOUN	B
among	O	ADP	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
hospital	I-P	NOUN	B
setting	I-P	NOUN	I
in	I-P	ADP	O
Taiwan	I-P	PROPN	B
.	I-P	PUNCT	O


Participants	B-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
intervention	I-I	NOUN	B
group	I-I	NOUN	I
(	I-I	PUNCT	O
n=50	I-I	ADJ	O
)	I-I	PUNCT	O
enrolled	I-I	VERB	O
in	I-I	ADP	O
a	I-I	DET	O
SHS	I-I	PROPN	B
prevention	I-I	NOUN	B
program	I-I	NOUN	I
based	I-I	VERB	O
on	I-I	ADP	O
the	I-I	DET	O
HBM	I-I	PROPN	B
,	I-I	PUNCT	O
while	I-I	SCONJ	O
participants	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
comparison	I-I	NOUN	B
group	I-I	NOUN	B
(	I-I	PUNCT	O
n=50	I-I	ADJ	O
)	I-I	PUNCT	O
received	I-I	VERB	O
standard	I-I	ADJ	B
government-mandated	I-I	ADJ	B
counseling	I-I	NOUN	I
care	I-I	NOUN	I
.	I-I	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
results	O	NOUN	B
should	O	AUX	O
encourage	O	VERB	O
health	O	NOUN	B
professionals	O	NOUN	I
to	O	PART	O
educate	O	VERB	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
regarding	O	VERB	O
the	O	DET	O
harms	O	NOUN	B
of	O	ADP	O
SHS	O	PROPN	B
while	O	SCONJ	O
both	O	DET	O
empowering	O	VERB	B
and	O	CCONJ	O
equipping	O	VERB	B
them	O	PRON	O
with	O	ADP	O
the	O	DET	O
tools	O	NOUN	B
to	O	PART	O
confront	O	VERB	O
their	O	PRON	O
family	O	NOUN	B
members	O	NOUN	I
and	O	CCONJ	O
effectively	O	ADV	O
reduce	O	VERB	O
their	O	PRON	O
SHS	B-OUT	PROPN	B
exposure	I-OUT	NOUN	B
while	O	SCONJ	O
promoting	O	VERB	B
smoke-free	O	ADJ	B
social	O	ADJ	B
norms	O	NOUN	I
.	O	PUNCT	O


INTERPRETATION	O	NOUN	B
AND	O	CCONJ	O
CONCLUSIONS	O	NOUN	O
Both	O	DET	O
schemes	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
radiotherapy	O	NOUN	B
produce	O	VERB	O
high	O	ADJ	O
percentages	O	NOUN	B
of	O	ADP	O
CR	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
low	I-OUT	ADJ	B
risk	I-OUT	NOUN	I
of	I-OUT	ADP	O
relapse	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
an	I-OUT	DET	O
acceptable	I-OUT	ADJ	O
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
benefits	O	NOUN	B
of	O	ADP	O
including	O	VERB	O
clinical	O	ADJ	B
factors	O	NOUN	I
in	O	ADP	O
rectal	O	ADJ	B
normal	O	ADJ	I
tissue	O	NOUN	I
complication	B-I	NOUN	O
probability	I-I	NOUN	O
modeling	I-I	NOUN	O
after	I-P	ADP	O
radiotherapy	I-P	NOUN	B
for	I-P	ADP	O
prostate	I-P	NOUN	B
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


Two	B-I	NUM	O
traditional	I-I	ADJ	O
dose-based	I-I	ADJ	O
models	I-I	NOUN	O
(	I-I	PUNCT	O
Lyman-Kutcher-Burman	I-I	NOUN	B
(	I-I	PUNCT	I
LKB	I-I	PROPN	I
)	I-I	PUNCT	O
and	I-I	CCONJ	O
Relative	I-I	ADJ	B
Seriality	I-I	NOUN	I
(	I-I	PUNCT	O
RS	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-I	CCONJ	O
a	I-I	DET	O
logistic	I-I	ADJ	B
model	I-I	NOUN	I
were	O	AUX	O
fitted	O	VERB	O
using	O	VERB	O
a	O	DET	O
maximum	O	ADJ	B
likelihood	O	NOUN	O
approach	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
whether	O	SCONJ	O
a	O	DET	O
shortened	O	VERB	B
postpartum	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
magnesium	B-I	NOUN	B
sulphate	I-I	NOUN	I
is	O	AUX	O
as	O	ADV	O
effective	O	ADJ	B
as	O	ADP	O
the	O	DET	O
standard	O	ADJ	B
Pritchard	O	PROPN	B
regimen	O	NOUN	I
in	O	ADP	O
controlling	O	VERB	B
fits	O	NOUN	O
in	O	ADP	O
eclampsia	O	NOUN	B
Between	B-P	ADP	O
January	I-P	PROPN	B
and	I-P	CCONJ	O
June	I-P	PROPN	O
2011	I-P	NUM	O
,	I-P	PUNCT	O
98	I-P	NUM	O
eclamptic	I-P	ADJ	B
mothers	I-P	NOUN	B
presenting	I-P	VERB	B
at	I-P	ADP	O
the	I-P	DET	O
labour	I-P	ADJ	B
ward	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
University	I-P	PROPN	B
of	I-P	ADP	I
Maiduguri	I-P	PROPN	I
Teaching	I-P	PROPN	I
Hospital	I-P	PROPN	I
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
the	O	DET	O
standard	B-I	ADJ	B
Pritchard	I-I	PROPN	B
regimen	I-I	NOUN	I
of	I-I	ADP	O
magnesium	I-I	NOUN	B
sulphate	I-I	NOUN	I
or	O	CCONJ	O
a	O	DET	O
shortened	B-I	VERB	B
postpartum	I-I	NOUN	B
course	I-I	NOUN	I
in	O	ADP	O
which	O	DET	O
only	O	ADV	O
two	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
intramuscular	B-I	ADJ	B
magnesium	I-I	NOUN	B
sulphate	I-I	NOUN	I
is	O	AUX	O
given	O	VERB	O
four	O	NUM	O
hours	O	NOUN	B
apart	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
shortened	O	VERB	B
postpartum	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
magnesium	B-I	NOUN	B
sulphate	I-OUT	NOUN	I
is	O	AUX	O
as	O	ADV	O
effective	B-OUT	ADJ	B
as	O	ADP	O
the	O	DET	O
standard	O	ADJ	B
Pritchard	O	PROPN	B
regimen	O	NOUN	I
in	O	ADP	O
the	O	DET	O
management	B-OUT	NOUN	B
of	I-OUT	ADP	O
eclampsia	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


PoC	O	PROPN	B
tests	O	NOUN	I
measured	O	VERB	B
(	O	PUNCT	O
and	O	CCONJ	O
devices	O	NOUN	B
used	O	VERB	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
were	O	AUX	O
haemoglobin	B-OUT	NOUN	B
A1c	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urine	I-OUT	NOUN	B
albumin	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
creatinine	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
DCA	I-OUT	NOUN	B
2000	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
lipids	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
Cholestech	I-OUT	NOUN	B
LDX	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
international	I-OUT	ADJ	B
normalized	I-OUT	VERB	O
ratio	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
CoaguChek	I-OUT	NOUN	B
S	I-OUT	PROPN	I
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


PoCT	B-P	NOUN	B
device	I-P	NOUN	O
operators	I-P	NOUN	O
were	O	AUX	O
provided	O	VERB	O
with	O	ADP	O
a	O	DET	O
colour-coded	B-I	ADJ	B
QC	I-I	PROPN	I
Result	I-I	PROPN	I
Sheet	I-I	PROPN	B
and	I-I	CCONJ	O
QC	I-I	PROPN	B
Action	I-I	PROPN	B
Sheet	I-I	PROPN	I
for	I-I	ADP	O
on-site	I-I	ADJ	B
recording	I-I	NOUN	O
and	I-I	CCONJ	O
interpreting	I-I	NOUN	B
of	I-I	ADP	O
their	I-I	PRON	O
results	I-I	NOUN	B
.	I-I	PUNCT	O


Median	B-OUT	ADJ	B
within-practice	I-OUT	NOUN	O
imprecision	I-OUT	NOUN	B
met	O	VERB	O
the	O	DET	O
analytical	O	ADJ	B
goals	O	NOUN	I
for	O	ADP	O
all	O	DET	O
PoC	O	PROPN	B
tests	O	NOUN	I
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
high-density	B-OUT	ADJ	B
lipoprotein-cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
HDL-C	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
where	O	SCONJ	O
observed	O	VERB	O
performance	O	NOUN	B
was	O	AUX	O
outside	O	ADP	O
the	O	DET	O
minimum	O	ADJ	B
goal	O	NOUN	B
for	O	ADP	O
one	O	NUM	O
level	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
lot	O	NOUN	O
number	O	NOUN	O
of	O	ADP	O
QC	O	PROPN	B
.	O	PUNCT	O


Most	O	ADJ	O
practices	O	NOUN	B
achieved	O	VERB	O
the	O	DET	O
imprecision	B-OUT	NOUN	B
goals	O	NOUN	B
for	O	ADP	O
all	O	DET	O
analytes	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
principal	O	ADJ	B
exception	O	NOUN	O
of	O	ADP	O
HDL-C	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
this	O	DET	O
study	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
acceptability	I-OUT	NOUN	B
of	O	ADP	O
6	O	NUM	O
%	O	NOUN	O
cellulose	B-I	NOUN	B
sulfate	I-I	NOUN	I
(	I-I	PUNCT	O
CS	I-I	ADJ	B
)	I-I	PUNCT	O
gel	O	NOUN	O
as	O	ADP	O
a	O	DET	O
vaginal	O	ADJ	B
microbicide	O	NOUN	I
in	B-P	ADP	O
sexually	I-P	ADV	B
abstinent	I-P	VERB	I
and	I-P	CCONJ	O
active	I-P	ADJ	O
HIV-infected	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty-nine	B-P	NUM	O
HIV-infected	I-P	ADJ	B
women	I-P	NOUN	B
were	O	AUX	O
enrolled	O	VERB	O
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
double-blind	O	ADJ	I
placebo-controlled	B-I	ADJ	I
study	O	NOUN	I
comparing	O	VERB	B
6	O	NUM	O
%	O	NOUN	O
CS	B-I	ADJ	B
to	I-I	PART	O
placebo	I-I	ADJ	B
gel	I-I	NOUN	I
used	O	VERB	O
for	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Sexually	B-P	ADV	B
abstinent	I-P	ADJ	I
women	I-P	NOUN	B
applied	O	VERB	O
gel	O	NOUN	B
once	O	ADV	O
or	O	CCONJ	O
twice	O	ADV	O
daily	O	ADV	B
and	O	CCONJ	O
sexually	O	ADV	B
active	O	ADJ	I
women	O	NOUN	B
used	O	VERB	O
gel	O	NOUN	B
once	O	ADV	B
daily	O	ADV	I
.	O	PUNCT	O


RESULTS	O	VERB	B
CS	O	ADJ	B
gel	O	NOUN	I
was	O	AUX	O
safe	O	ADJ	O
with	O	ADP	O
no	O	DET	O
reported	O	VERB	O
severe	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
life-threatening	I-OUT	ADJ	B
adverse	I-OUT	ADJ	O
events	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
AE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Fewer	O	ADJ	O
women	O	NOUN	B
(	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
used	O	VERB	O
CS	O	PROPN	B
experienced	O	VERB	O
urogenital	B-OUT	ADJ	B
AE	I-OUT	NOUN	B
than	O	ADP	O
those	O	DET	O
assigned	O	VERB	O
to	O	PART	O
placebo	B-I	ADJ	B
gel	O	NOUN	I
(	O	PUNCT	O
70	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.59	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Eleven	O	NUM	O
(	O	PUNCT	O
19	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
women	O	NOUN	B
experienced	O	VERB	O
intermenstrual	B-OUT	ADJ	B
bleeding	I-OUT	NOUN	I
judged	O	VERB	O
to	O	PART	O
be	O	AUX	O
probably	O	ADV	O
or	O	CCONJ	O
possibly	O	ADV	O
related	O	ADJ	O
to	O	PART	O
gel	O	NOUN	B
use	O	NOUN	O
(	O	PUNCT	O
four	O	NUM	O
in	O	ADP	O
the	O	DET	O
CS	O	PROPN	B
and	O	CCONJ	O
seven	O	NUM	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
gel	O	NOUN	I
group	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
Phase	O	NOUN	B
I	O	NUM	I
study	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
CS	B-I	ADJ	B
vaginal	I-I	ADJ	I
gel	I-I	NOUN	I
was	O	AUX	O
safe	B-OUT	ADJ	O
,	I-OUT	PUNCT	O
well	I-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	I-OUT	CCONJ	O
acceptable	I-OUT	ADJ	B
by	O	ADP	O
HIV-infected	B-P	ADJ	B
women	I-P	NOUN	B
and	I-P	CCONJ	O
their	I-P	PRON	O
male	I-P	NOUN	B
partners	I-P	NOUN	B
.	I-P	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
traumatic	O	ADJ	B
arthrotomy	O	NOUN	O
of	O	ADP	O
the	O	DET	O
knee	O	NOUN	B
using	O	VERB	O
the	O	DET	O
saline	B-I	NOUN	B
solution	I-I	NOUN	I
load	I-I	NOUN	O
test	I-I	NOUN	O
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
saline	B-I	NOUN	B
solution	I-I	NOUN	I
load	I-I	NOUN	O
test	I-I	NOUN	O
helps	O	VERB	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
a	O	DET	O
wound	O	NOUN	B
extends	O	VERB	O
into	O	ADP	O
the	O	DET	O
knee	O	NOUN	B
joint	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Fifty-six	B-P	NUM	O
consecutive	I-P	ADJ	B
patients	I-P	NOUN	B
scheduled	I-P	VERB	O
for	I-P	ADP	O
knee	I-P	NOUN	B
arthroscopy	I-P	NOUN	I
were	O	AUX	O
enrolled	O	VERB	O
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
included	O	VERB	O
thirty-one	B-P	NUM	O
female	I-P	ADJ	B
patients	I-P	NOUN	B
and	I-P	CCONJ	O
twenty-five	I-P	ADJ	O
male	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
combined	I-P	ADJ	O
average	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
fifty	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
an	I-P	DET	O
average	I-OUT	ADJ	B
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
of	I-P	ADP	O
30.9	I-P	NUM	O
.	I-P	PUNCT	O


The	O	DET	O
mean	B-OUT	ADJ	O
volumes	I-OUT	NOUN	B
of	I-OUT	ADP	O
injected	I-OUT	VERB	B
fluid	I-OUT	NOUN	I
needed	I-OUT	VERB	O
for	I-OUT	ADP	O
a	I-OUT	DET	O
positive	I-OUT	ADJ	B
result	I-OUT	NOUN	B
at	I-OUT	ADP	O
the	I-OUT	DET	O
inferomedial	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
superomedial	I-OUT	ADJ	B
needle	I-OUT	NOUN	I
locations	I-OUT	NOUN	B
were	O	AUX	O
64.0	O	NUM	O
and	O	CCONJ	O
95.2	O	NUM	O
mL	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
this	O	DET	O
difference	O	NOUN	O
was	O	AUX	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
correlation	I-OUT	NOUN	B
between	I-OUT	ADP	O
necessary	I-OUT	ADJ	O
injection	I-OUT	NOUN	B
volume	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
sex	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
knee	I-OUT	NOUN	B
circumference	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Sustained	O	ADJ	B
effect	O	NOUN	B
of	O	ADP	O
SQ-standardized	O	ADJ	B
grass	O	NOUN	I
allergy	O	NOUN	O
immunotherapy	B-I	NOUN	B
tablet	I-I	NOUN	B
on	O	ADP	O
rhinoconjunctivitis	O	NOUN	B
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
sustained	O	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
during	O	ADP	O
the	O	DET	O
grass	O	NOUN	B
pollen	O	NOUN	B
season	O	NOUN	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
SQ-standardized	O	ADJ	B
grass	B-I	NOUN	I
allergy	I-I	NOUN	O
immunotherapy	I-I	NOUN	O
tablet	I-I	NOUN	B
(	I-I	PUNCT	O
AIT	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
Graza	O	PROPN	B
(	O	PUNCT	O
Phleum	O	PROPN	B
pratense	O	NOUN	I
75,000	O	NUM	O
SQ-T/2800	O	NOUN	B
BAU	O	NOUN	B
;	O	PUNCT	O
ALK	O	NOUN	B
,	O	PUNCT	O
Denmark	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Quality	B-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
assessments	O	NOUN	I
were	O	AUX	O
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
standardized	B-OUT	ADJ	B
rhinoconjunctivitis	I-OUT	NOUN	I
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
questionnaire	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RQLQ	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
S	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
completed	O	VERB	O
weekly	O	ADV	B
during	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
grass	O	NOUN	B
pollen	O	NOUN	B
season	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
During	O	ADP	O
follow-up	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	O	ADJ	B
RQLQ	B-OUT	NOUN	I
(	I-OUT	PUNCT	O
S	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
score	I-OUT	NOUN	O
for	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
grass	O	NOUN	B
pollen	O	NOUN	B
season	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
active	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
relative	O	ADJ	O
difference	O	NOUN	O
to	O	PART	O
placebo	B-I	NOUN	B
:	I-I	PUNCT	O
23	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Improvements	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
all	O	DET	O
seven	O	NUM	O
RQLQ	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
S	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
domains	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
subjects	O	NOUN	B
inadequately	O	ADV	B
controlled	O	VERB	B
by	O	ADP	O
symptomatic	O	ADJ	B
medications	O	NOUN	B
,	O	PUNCT	O
grass	O	NOUN	B
AIT	B-I	NOUN	B
provided	O	VERB	O
sustained	O	ADJ	B
and	O	CCONJ	O
clinically	O	ADV	B
relevant	O	ADJ	O
improvements	O	NOUN	B
in	O	ADP	O
rhinoconjunctivitis	B-OUT	NOUN	B
quality	I-OUT	NOUN	B
of	I-OUT	ADP	I
life	I-OUT	NOUN	I
compared	O	VERB	O
to	O	PART	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


HORIZON	O	NOUN	B
is	O	AUX	O
a	O	DET	O
trauma	B-I	NOUN	B
focused	I-I	VERB	O
cognitive	I-I	ADJ	B
behavioral	I-I	ADJ	I
therapy	I-I	NOUN	I
based	O	VERB	O
group	O	NOUN	B
program	O	NOUN	I
with	O	ADP	O
the	O	DET	O
added	O	VERB	O
component	O	NOUN	O
of	O	ADP	O
a	O	DET	O
preparatory	B-I	ADJ	B
parenting	I-I	NOUN	B
program	I-I	NOUN	I
aimed	O	VERB	O
at	O	ADP	O
improving	O	VERB	B
parental	O	ADJ	B
availability	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
added	O	VERB	O
component	O	NOUN	O
of	O	ADP	O
parent-child	O	ADJ	B
sessions	O	NOUN	B
to	O	PART	O
improve	O	VERB	B
parent-child	O	ADJ	B
interaction	O	NOUN	B
.	O	PUNCT	O


Primary	O	ADJ	B
outcome	O	NOUN	I
measures	O	NOUN	I
are	B-OUT	AUX	O
posttraumatic	I-OUT	ADJ	B
stress	I-OUT	NOUN	I
symptoms	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
internalizing	I-OUT	VERB	B
and	I-OUT	CCONJ	O
externalizing	I-OUT	VERB	B
problems	I-OUT	NOUN	I
in	I-OUT	ADP	O
children	I-OUT	NOUN	B
.	O	PUNCT	O


The	O	DET	O
secondary	O	ADJ	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
test	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
added	O	VERB	O
components	B-OUT	NOUN	B
on	I-OUT	ADP	O
adjustment	I-OUT	NOUN	B
problems	I-OUT	NOUN	I
in	I-OUT	ADP	O
children	I-OUT	NOUN	B
and	O	CCONJ	O
to	O	PART	O
test	O	VERB	B
whether	O	SCONJ	O
enhanced	O	VERB	B
effects	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
explained	B-OUT	VERB	O
by	I-OUT	ADP	O
changes	I-OUT	NOUN	B
in	I-OUT	ADP	O
children	I-OUT	NOUN	B
's	I-OUT	PART	I
responses	I-OUT	NOUN	B
towards	O	ADP	O
experienced	O	ADJ	B
violence	O	NOUN	B
,	O	PUNCT	O
in	B-OUT	ADP	O
parental	I-OUT	ADJ	B
availability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
in	I-OUT	ADP	O
quality	I-OUT	NOUN	B
of	I-OUT	ADP	O
parent-child	I-OUT	ADJ	B
interaction	I-OUT	NOUN	B
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
will	O	AUX	O
enhance	O	VERB	B
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
the	O	DET	O
efficacy	B-I	NOUN	B
interparental	I-I	ADJ	B
violence-related	I-I	ADJ	B
parental	I-I	ADJ	I
components	I-I	NOUN	I
added	I-I	VERB	O
to	I-I	ADP	O
trauma	I-I	NOUN	B
focused	I-I	VERB	O
cognitive	I-I	ADJ	B
behavioral	I-I	ADJ	O
group	I-I	NOUN	O
program	I-I	NOUN	O
for	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
been	O	AUX	O
exposed	O	VERB	O
to	O	ADP	O
IPV	O	PROPN	B
.	O	PUNCT	O


METHODS	O	VERB	O
A	B-P	DET	O
consecutive	I-P	ADJ	B
cohort	I-P	NOUN	B
of	I-P	ADP	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
200	I-P	NUM	O
,	I-P	PUNCT	O
68	I-P	NUM	O
men	I-P	NOUN	B
)	I-P	PUNCT	O
referred	I-P	VERB	O
to	I-P	PART	O
acute	I-I	ADJ	B
surgical	I-I	ADJ	O
correction	I-I	NOUN	O
of	I-I	ADP	O
hip	I-I	NOUN	B
fracture	I-I	NOUN	I
was	I-P	AUX	O
studied	I-P	VERB	O
.	I-P	PUNCT	O


Troponin	B-I	NOUN	B
T	I-I	NOUN	I
(	I-I	PUNCT	O
TnT	I-I	NOUN	B
)	I-I	PUNCT	O
measurements	I-I	NOUN	B
and	O	CCONJ	O
electrocardiographic	B-I	ADJ	B
(	I-I	PUNCT	I
ECG	I-I	PROPN	O
)	I-I	PUNCT	O
recordings	I-I	NOUN	B
were	O	AUX	O
performed	O	VERB	O
at	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
before	O	ADP	O
operation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
first	O	ADJ	O
and	O	CCONJ	O
2nd	O	ADJ	O
postoperative	O	ADJ	B
days	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
used	O	VERB	O
for	O	ADP	O
diagnosis	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
rise	B-OUT	NOUN	O
in	I-OUT	ADP	O
TnT	I-OUT	NOUN	B
as	O	ADP	O
a	O	DET	O
sign	O	NOUN	B
of	O	ADP	O
myocardial	B-OUT	ADJ	B
infarction	I-OUT	NOUN	I
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
71	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
35.5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
25	O	NUM	O
of	O	ADP	O
them	O	PRON	O
had	O	AUX	O
a	O	DET	O
TnT	B-OUT	NOUN	B
elevation	I-OUT	NOUN	B
exceeding	O	VERB	O
five	O	NUM	O
times	O	NOUN	O
the	O	DET	O
upper	O	ADJ	B
normal	O	ADJ	I
limit	O	NOUN	I
.	O	PUNCT	O


Evidence-based	B-OUT	ADJ	B
medications	I-OUT	NOUN	I
of	O	ADP	O
myocardial	O	ADJ	B
infarction	O	NOUN	I
were	O	AUX	O
seldom	O	ADV	B
started	O	VERB	B
and	O	CCONJ	O
cardiologist	O	NOUN	B
was	O	AUX	O
consulted	O	VERB	B
in	O	ADP	O
12	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
16.9	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


How	O	SCONJ	O
to	O	PART	O
establish	O	VERB	O
equivalence	O	NOUN	B
when	O	SCONJ	O
data	O	NOUN	B
are	O	AUX	O
censored	O	VERB	B
:	O	PUNCT	O
a	O	DET	O
randomized	B-P	ADJ	B
trial	I-P	NOUN	I
of	I-P	ADP	O
treatments	I-P	NOUN	B
for	I-P	ADP	O
B	I-P	NOUN	B
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
usual	O	ADJ	O
logrank	B-I	NOUN	B
test	I-I	NOUN	I
has	O	AUX	O
to	O	PART	O
be	O	AUX	O
modified	O	VERB	O
to	O	PART	O
test	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
true	O	ADJ	B
value	O	NOUN	I
r	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
hazard	O	NOUN	B
rates	O	NOUN	I
in	O	ADP	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
is	O	AUX	O
at	O	ADP	O
least	O	ADV	O
equal	O	ADJ	O
to	O	PART	O
a	O	DET	O
limit	O	NOUN	B
value	O	NOUN	I
r0	O	NOUN	I
.	O	PUNCT	O


Ambulatory	B-OUT	ADJ	B
BP	I-OUT	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
the	O	DET	O
final	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
each	O	DET	O
phase	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
Compared	O	VERB	O
with	O	ADP	O
the	O	DET	O
placebo	O	NOUN	B
phase	O	NOUN	O
,	O	PUNCT	O
end	O	NOUN	O
of	O	ADP	O
phase	O	NOUN	B
clinic	B-OUT	NOUN	I
BP	I-OUT	NOUN	B
was	O	AUX	O
unchanged	O	ADJ	B
by	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
progestogen	O	NOUN	B
treatments	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
a	O	DET	O
regimen	O	NOUN	B
of	O	ADP	O
postmenopausal	O	ADJ	B
hormone	O	NOUN	I
replacement	O	NOUN	I
therapy	O	NOUN	I
with	O	ADP	O
a	O	DET	O
fixed	O	ADJ	O
mid-range	O	ADJ	O
daily	O	ADJ	O
dose	O	NOUN	O
of	O	ADP	O
CEE	B-I	NOUN	B
combined	O	VERB	B
with	O	ADP	O
a	O	DET	O
cyclical	O	ADJ	B
regimen	O	NOUN	B
of	O	ADP	O
a	O	DET	O
C21	O	NOUN	B
progestogen	O	NOUN	I
spanning	O	VERB	O
the	O	DET	O
current	O	ADJ	O
clinical	O	ADJ	B
dose	O	NOUN	I
range	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
progestogen	B-I	NOUN	B
has	O	AUX	O
either	O	CCONJ	O
no	O	DET	B
effect	O	NOUN	I
or	O	CCONJ	O
a	O	DET	O
small	O	ADJ	O
dose-dependent	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
clinic	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
ambulatory	I-OUT	ADJ	B
BPs	I-OUT	NOUN	B
over	O	ADP	O
one	O	NUM	O
treatment	O	NOUN	B
cycle	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	O	CCONJ	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
atomoxetine	B-I	NOUN	B
monotherapy	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
combined	O	ADJ	O
atomoxetine/fluoxetine	B-I	NOUN	B
therapy	I-I	NOUN	I
in	O	ADP	O
a	O	DET	O
population	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
ADHD	I-P	NOUN	B
and	I-P	CCONJ	O
concurrent	I-P	ADJ	B
symptoms	I-P	NOUN	B
of	I-P	ADP	O
depression	I-P	NOUN	B
or	I-P	CCONJ	O
anxiety	I-P	NOUN	B
.	I-P	PUNCT	O


Some	O	DET	O
differences	B-OUT	NOUN	O
between	O	ADP	O
treatment	O	NOUN	B
groups	O	NOUN	I
for	O	ADP	O
depressive	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
were	O	AUX	O
significant	B-OUT	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
magnitudes	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
small	B-OUT	ADJ	B
and	O	CCONJ	O
likely	O	ADJ	O
of	O	ADP	O
limited	O	ADJ	O
clinical	O	ADJ	B
importance	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
combination	O	NOUN	B
group	O	NOUN	I
had	O	AUX	O
greater	B-OUT	ADJ	O
increases	I-OUT	NOUN	B
in	I-OUT	ADP	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
pulse	I-OUT	NOUN	B
than	O	ADP	O
did	O	AUX	O
the	O	DET	O
monotherapy	O	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


Anxiety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
depressive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
also	O	ADV	O
improved	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
placebo-only	O	ADJ	O
arm	O	NOUN	O
does	O	AUX	O
not	O	PART	O
allow	O	VERB	O
us	O	PRON	O
to	O	PART	O
conclude	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
effects	O	NOUN	B
are	O	AUX	O
specifically	O	ADV	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
atomoxetine	B-I	NOUN	B
.	I-I	PUNCT	O


Combined	B-I	ADJ	B
atomoxetine/fluoxetine	I-I	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
.	O	PUNCT	O


Double-blind	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
trandolapril	B-I	NOUN	B
2	O	NUM	I
mg	O	NOUN	I
and	O	CCONJ	O
hydrochlorothiazide	B-I	NOUN	B
25	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
essential	I-P	ADJ	I
hypertension	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
multicenter	O	NOUN	B
international	O	ADJ	I
trial	O	NOUN	I
recruited	O	VERB	O
205	B-P	NUM	O
patients	I-P	NOUN	B
from	I-P	ADP	O
16	I-P	NUM	O
investigators	I-P	NOUN	B
.	I-P	PUNCT	O


After	O	ADP	O
a	O	DET	O
4-week	O	NOUN	B
,	O	PUNCT	O
single-blind	B-I	ADJ	B
placebo	I-I	NOUN	B
run-in	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
16	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
trandolapril	B-I	NOUN	B
2	O	NUM	I
mg/day	O	NOUN	B
(	O	PUNCT	O
68	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
hydrochlorothiazide	B-I	NOUN	B
(	I-I	PUNCT	O
HCTZ	I-I	NOUN	B
)	I-I	PUNCT	O
25	O	NUM	O
mg/day	O	NOUN	B
(	O	PUNCT	O
68	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
or	B-I	CCONJ	O
the	I-I	DET	O
combination	I-I	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
was	O	AUX	O
normalized	O	VERB	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
group	O	NOUN	I
in	O	ADP	O
67	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
proportion	O	NOUN	B
than	O	ADP	O
either	O	CCONJ	O
trandolapril	O	NOUN	B
(	O	PUNCT	O
63	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
HCTZ	O	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
drugs	O	NOUN	B
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
enhance	O	VERB	B
the	O	DET	O
antihypertensive	B-OUT	ADJ	B
effect	I-OUT	NOUN	I
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
compounds	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
diltiazem	B-I	NOUN	B
and	I-I	CCONJ	O
propranolol	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
unstable	I-P	ADJ	B
angina	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	VERB	O
Fifty-six	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
unstable	I-P	ADJ	B
angina	I-P	NOUN	I
,	I-P	PUNCT	O
mean	I-P	VERB	O
age	I-P	NOUN	B
of	I-P	ADP	O
55.4	I-P	NUM	O
+/-	I-P	CCONJ	O
8.5	I-P	NUM	O
,	I-P	PUNCT	O
41	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
15	I-P	NUM	O
women	I-P	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
diltiazem	B-I	NOUN	B
or	I-I	CCONJ	O
propranolol	I-I	NOUN	B
at	O	ADP	O
total	O	ADJ	O
daily	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
180	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
120	O	NUM	O
mg	O	NOUN	O
respectively	O	ADV	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
48	O	NUM	O
hours	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
48	O	NUM	O
hours	O	NOUN	B
,	O	PUNCT	O
four	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
,	O	PUNCT	O
clinical	B-OUT	ADJ	B
evaluation	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
CKMB	I-OUT	NOUN	B
data	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
ECG	I-OUT	PROPN	B
were	O	AUX	O
obtained	O	VERB	O
and	O	CCONJ	O
two	O	NUM	O
times	O	NOUN	O
daily	O	ADV	B
until	O	ADP	O
7th	O	ADJ	O
day	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
SAP	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
DAP	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
HR	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
RR	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
statistical	O	ADJ	B
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


Moisture-vapour-permeable	B-I	ADJ	B
film	I-I	NOUN	B
as	O	ADP	O
an	O	DET	O
outpatient	B-P	ADJ	B
burn	I-P	NOUN	B
dressing	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
MVPF	B-I	PROPN	B
group	O	NOUN	B
demonstrated	O	VERB	O
a	O	DET	O
39.0	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
greater	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
pain	B-OUT	NOUN	B
after	O	ADP	O
application	O	NOUN	B
of	O	ADP	O
the	O	DET	O
dressing	O	NOUN	B
over	O	ADP	O
the	O	DET	O
silver	B-I	ADJ	B
sulphadiazine	I-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
haloperidol	B-I	NOUN	B
on	O	ADP	O
behavioral	B-OUT	ADJ	B
symptoms	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
learning	I-OUT	NOUN	B
were	O	AUX	O
critically	O	ADV	O
assessed	O	VERB	B
in	O	ADP	O
autistic	B-P	ADJ	B
children	I-P	NOUN	O
in	O	ADP	O
an	O	DET	O
ongoing	O	ADJ	O
double-blind	O	ADJ	B
placebo-controlled	B-I	ADJ	B
clinical	O	ADJ	B
trial	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
clear	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
morphine	B-OUT	NOUN	B
requirement	I-OUT	NOUN	B
became	O	VERB	O
evident	O	ADJ	O
after	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.010	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Hospital	B-OUT	PROPN	B
stay	I-OUT	VERB	I
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	B
in	O	ADP	O
the	O	DET	O
SH	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
SH	O	NOUN	B
2.2	O	NUM	O
+/-	O	CCONJ	O
1.2	O	NUM	O
[	O	PUNCT	O
0	O	NUM	O
;	O	PUNCT	O
5.0	O	NUM	O
]	O	PUNCT	O
versus	O	CCONJ	O
MM	B-I	NOUN	B
3.1	O	NUM	O
+/-	O	CCONJ	O
1.7	O	NUM	O
[	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
8.0	O	NUM	O
]	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
differences	B-OUT	NOUN	O
in	O	ADP	O
the	O	DET	O
resolution	B-OUT	NOUN	B
of	I-OUT	ADP	O
symptoms	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
2	O	NUM	O
groups	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
over	O	ADP	O
2	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	B-OUT	ADJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
complications	I-OUT	NOUN	B
was	O	AUX	O
the	O	DET	O
same	O	ADJ	O
,	O	PUNCT	O
specifically	O	ADV	O
fecaloma	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
MM	B-I	NOUN	B
group	O	NOUN	B
and	O	CCONJ	O
external	B-OUT	ADJ	B
hemorrhoidal	I-OUT	ADJ	B
thrombosis	I-OUT	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.006	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
SH	B-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
technique	O	NOUN	B
is	O	AUX	O
reproducible	O	ADJ	O
and	O	CCONJ	O
can	O	AUX	O
achieve	O	VERB	O
comparable	O	ADJ	O
outcomes	B-OUT	NOUN	B
as	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
MM	B-I	NOUN	B
technique	O	NOUN	B
as	O	ADV	O
long	O	ADV	O
as	O	ADP	O
the	O	DET	O
well-described	O	ADJ	O
steps	O	NOUN	O
of	O	ADP	O
the	O	DET	O
technique	O	NOUN	B
are	O	AUX	O
followed	O	VERB	O
.	O	PUNCT	O


Its	O	PRON	O
effectiveness	B-OUT	NOUN	B
in	O	ADP	O
relieving	O	VERB	B
symptoms	O	NOUN	B
is	O	AUX	O
equivalent	O	ADJ	O
to	O	PART	O
conventional	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
hemorrhoidal	I-OUT	ADJ	B
prolapse	I-OUT	NOUN	I
recurrences	I-OUT	NOUN	B
at	I-OUT	ADP	O
2	I-OUT	NUM	O
years	I-OUT	NOUN	B
is	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
randomised	O	ADJ	B
trial	O	NOUN	I
compared	O	VERB	O
20	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
leukaemia	I-P	NOUN	B
receiving	I-P	VERB	O
human	I-I	ADJ	B
recombinant	I-I	ADJ	O
granulocyte	I-I	NOUN	O
macrophage	I-I	NOUN	O
colony	I-I	NOUN	B
stimulating	I-I	NOUN	I
factor	I-I	NOUN	I
(	I-I	PUNCT	O
GM	I-I	PROPN	B
CSF	I-I	PROPN	B
)	I-I	PUNCT	O
,	I-P	PUNCT	O
with	I-P	ADP	O
20	I-P	NUM	O
patients	I-P	NOUN	B
receiving	I-P	VERB	O
placebo	I-I	NOUN	B
for	I-I	ADP	O
14	I-I	NUM	O
days	I-I	NOUN	B
after	I-I	ADP	O
allogeneic	I-I	ADJ	B
matched	I-I	ADJ	O
sibling	I-I	NOUN	B
bone	I-I	NOUN	B
marrow	I-I	NOUN	I
transplantation	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
neutrophil	I-OUT	NOUN	B
count	I-OUT	NOUN	O
at	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
GM	B-I	PROPN	B
CSF	I-I	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
1.90	O	NUM	O
vs.	O	CCONJ	O
0.46	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/l	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	I
hospital	I-OUT	NOUN	I
stay	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
antibiotic	I-OUT	ADJ	B
days	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
fever	I-OUT	NOUN	B
days	I-OUT	NOUN	B
was	O	AUX	O
the	O	DET	O
same	O	ADJ	O
for	O	ADP	O
both	B-P	CCONJ	O
patient	I-P	NOUN	B
groups	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
GM-CSF	B-I	NOUN	B
group	O	NOUN	B
had	O	AUX	O
lower	O	ADJ	B
haemoglobin	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
platelets	I-OUT	NOUN	B
counts	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
higher	I-OUT	ADJ	O
plasma	I-OUT	NOUN	B
urea	I-OUT	NOUN	O
creatinine	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
bilirubin	I-OUT	NOUN	B
,	O	PUNCT	O
than	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


Tumor	B-OUT	NOUN	B
budding	I-OUT	NOUN	I
is	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
in	O	ADP	O
AJCC/UICC	B-P	NOUN	B
stage	I-P	NOUN	I
II	I-P	NUM	I
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
infiltrating	O	VERB	B
growth	O	NOUN	B
pattern	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
histological	O	ADJ	B
subtype	O	NOUN	B
and	O	CCONJ	O
lymphovascular	O	ADJ	B
invasion	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
high-grade	O	ADJ	B
budding	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
tumor	B-OUT	NOUN	B
grade	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
lymphovascular	I-OUT	ADJ	B
invasion	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Cox	O	PROPN	B
's	O	PART	I
proportional	O	ADJ	B
hazards	O	NOUN	I
regression	O	NOUN	I
models	O	NOUN	I
proved	O	VERB	O
tumor	B-I	NOUN	B
budding	I-I	NOUN	I
to	O	PART	O
be	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
disease	B-OUT	NOUN	B
progression	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
3.91	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.3-11.77	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
cancer-related	I-OUT	ADJ	B
death	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
5.90	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.62-21.51	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.007	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Tumor	O	NOUN	B
budding	O	NOUN	I
independently	O	ADV	O
predicted	O	VERB	B
patient	O	NOUN	B
outcome	B-P	NOUN	O
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
AJCC/UICC	I-P	NOUN	B
stage	I-P	NOUN	I
II	I-P	NUM	I
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
therefore	O	ADV	O
be	O	AUX	O
used	O	VERB	O
for	O	ADP	O
accurate	O	ADJ	B
prognostication	O	NOUN	B
,	O	PUNCT	O
patient	O	NOUN	B
counseling	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
design	O	NOUN	B
of	O	ADP	O
clinical	O	ADJ	B
trials	O	NOUN	I
by	O	ADP	O
using	B-I	VERB	O
integrated	I-I	ADJ	O
multimodal	I-I	ADJ	B
therapy	I-I	NOUN	I
.	O	PUNCT	O


Early	O	ADV	B
versus	O	CCONJ	O
late	O	ADJ	B
hCG	B-I	NOUN	B
administration	I-I	NOUN	B
to	O	PART	O
trigger	O	VERB	B
ovulation	O	NOUN	B
in	O	ADP	O
mild	O	ADJ	B
stimulated	O	ADJ	O
IUI	O	NOUN	B
cycles	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
verify	O	VERB	O
non-inferiority	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
pregnancy	O	NOUN	I
rate	O	NOUN	O
of	O	ADP	O
Early	B-I	ADJ	B
hCG	I-I	NOUN	B
administration	I-I	NOUN	B
(	O	PUNCT	O
leading	O	VERB	O
follicle	O	NOUN	B
sizes	O	NOUN	B
within	O	ADP	O
16.0-16.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
diameter	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
Late	B-I	ADJ	B
hCG	I-I	NOUN	I
administration	I-I	NOUN	I
(	O	PUNCT	O
leading	O	VERB	O
follicle	O	NOUN	B
sizes	O	NOUN	B
within	O	ADP	O
18.0-18.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
diameter	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Six	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
twelve	I-P	NUM	O
infertile	I-P	ADJ	B
women	I-P	NOUN	B
candidates	I-P	NOUN	O
for	I-P	ADP	O
intrauterine	I-P	NOUN	B
insemination	I-P	NOUN	I
(	I-P	PUNCT	O
IUI	I-P	NOUN	B
)	I-P	PUNCT	O
received	O	VERB	O
HP-hMG	B-I	NOUN	B
75	O	NUM	O
IU/day	O	NOUN	O
SC	O	NOUN	B
from	O	ADP	O
cycle	O	NOUN	B
days	O	NOUN	I
4	O	NUM	O
to	O	PART	O
8	O	NUM	O
and	O	CCONJ	O
then	O	ADV	O
as	O	ADP	O
per	O	ADP	O
ovarian	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


Managing	O	VERB	O
repetitive	O	ADJ	B
behaviours	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
:	I-P	PUNCT	O
pilot	O	NOUN	B
randomised	O	VERB	I
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
parent	B-P	NOUN	B
group	O	NOUN	B
intervention	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
acceptability	O	NOUN	B
,	O	PUNCT	O
feasibility	O	NOUN	B
and	O	CCONJ	O
impact	O	VERB	B
on	O	ADP	O
child	O	NOUN	B
functioning	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
8	B-I	NUM	O
weeks	I-I	NOUN	B
parent-group	I-I	ADJ	B
intervention	I-I	NOUN	I
to	I-I	PART	O
manage	I-I	VERB	O
restricted	I-I	ADJ	B
and	I-I	CCONJ	O
repetitive	I-I	ADJ	B
behaviours	I-I	NOUN	I
(	I-P	PUNCT	O
RRB	I-P	NOUN	B
)	I-P	PUNCT	O
in	I-P	ADP	O
young	I-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
ASD	I-P	VERB	B
aged	I-P	ADJ	B
3-7	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
In	O	ADP	O
1998	O	NUM	O
,	O	PUNCT	O
mandatory	O	ADJ	O
folic	O	ADJ	B
acid	O	NOUN	I
fortification	O	NOUN	B
of	O	ADP	O
white	B-I	ADJ	B
flour	I-I	NOUN	I
and	I-I	CCONJ	O
select	I-I	VERB	O
cereal	I-I	NOUN	B
grain	I-I	NOUN	O
products	I-I	NOUN	B
was	O	AUX	O
implemented	O	VERB	O
in	O	ADP	O
Canada	B-P	PROPN	B
with	O	ADP	O
the	O	DET	O
intention	O	NOUN	B
to	O	PART	O
increase	O	VERB	B
dietary	B-I	ADJ	B
folate	I-I	NOUN	B
intakes	I-I	NOUN	B
of	O	ADP	O
reproducing	B-P	VERB	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
response	O	NOUN	B
to	O	PART	O
improved	O	VERB	B
blood	O	NOUN	B
folate	O	NOUN	I
concentrations	O	NOUN	I
,	O	PUNCT	O
many	O	ADJ	O
health	O	NOUN	B
care	O	NOUN	I
professionals	O	NOUN	I
are	O	AUX	O
asking	O	VERB	O
whether	O	SCONJ	O
a	O	DET	O
folic	B-I	ADJ	B
acid	I-I	NOUN	I
supplement	I-I	NOUN	I
is	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
NTD	O	NOUN	B
prevention	O	NOUN	B
among	O	ADP	O
women	B-P	NOUN	B
with	I-P	ADP	O
high	I-P	ADJ	B
blood	I-P	NOUN	O
folate	I-P	NOUN	O
values	I-P	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
how	O	SCONJ	O
reliably	O	ADV	O
high	O	ADJ	O
RBC	O	NOUN	B
folate	O	NOUN	B
concentrations	O	NOUN	I
predict	O	VERB	O
folate	O	NOUN	B
intakes	O	NOUN	B
shown	O	VERB	O
in	O	ADP	O
randomized	O	ADJ	B
controlled	O	ADJ	I
trials	O	NOUN	I
to	O	PART	O
be	O	AUX	O
protective	O	ADJ	O
against	O	ADP	O
NTDs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
how	O	SCONJ	O
predictive	O	ADJ	B
blood	B-OUT	NOUN	B
folate	I-OUT	NOUN	O
concentrations	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
folate	I-OUT	NOUN	B
intakes	I-OUT	NOUN	O
are	O	AUX	O
of	O	ADP	O
each	O	DET	O
other	O	ADJ	O
in	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
well-educated	B-P	ADJ	O
lactating	I-P	VERB	B
Canadian	I-P	ADJ	B
women	I-P	NOUN	B
exposed	I-P	VERB	B
to	I-P	PART	I
high	I-P	ADJ	O
levels	I-P	NOUN	B
of	I-P	ADP	O
synthetic	I-P	ADJ	B
folate	I-P	NOUN	I
.	I-P	PUNCT	O


More	O	ADJ	O
studies	O	NOUN	B
are	O	AUX	O
needed	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
blood	B-OUT	NOUN	B
folate	I-OUT	NOUN	O
concentration	I-OUT	NOUN	B
and	O	CCONJ	O
NTD	O	NOUN	B
risk	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
initial	O	ADJ	O
preparation	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
defects	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
in	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
to	O	PART	O
either	O	CCONJ	O
GTR-group	B-I	ADJ	B
or	I-P	CCONJ	O
OFD-group	I-I	ADJ	B
.	I-P	PUNCT	O


The	O	DET	O
radiographs	B-I	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
by	O	ADP	O
subtraction	O	NOUN	B
radiography	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
Comparing	O	VERB	O
baseline	O	NOUN	B
to	O	PART	O
6-month	O	ADJ	O
results	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
groups	O	NOUN	B
showed	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
probing	B-OUT	NOUN	B
depth	I-OUT	NOUN	I
reduction	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
horizontal	I-OUT	ADJ	B
clinical	I-OUT	ADJ	B
attachment	I-OUT	NOUN	I
level	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CAL-h	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
gain	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
increase	I-OUT	NOUN	B
in	I-OUT	ADP	O
gingival	I-OUT	ADJ	B
recession	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
GR	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Comparing	O	VERB	B
the	O	DET	O
two	O	NUM	O
treatments	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
PD	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
1.67	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
2.51	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.26	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
CAL-v	B-OUT	NOUN	B
gain	I-OUT	NOUN	B
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
0.62	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
1.16	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P=	O	NOUN	O
0.37	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
GR	B-OUT	NOUN	B
increase	I-OUT	NOUN	B
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
1.04	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
1.24	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.31	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


GTR	B-I	NOUN	B
provided	O	VERB	O
complete	O	ADJ	O
closure	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
furcation	I-OUT	NOUN	B
defect	I-OUT	NOUN	O
in	O	ADP	O
two	O	NUM	O
sites	O	NOUN	B
and	O	CCONJ	O
superior	B-OUT	ADJ	B
horizontal	I-OUT	ADJ	B
clinical	I-OUT	ADJ	B
attachment	I-OUT	NOUN	O
level	I-OUT	NOUN	O
gain	I-OUT	NOUN	O
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
2.27	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
1.01	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Utilization	O	NOUN	B
of	O	ADP	O
health	B-I	NOUN	B
care	I-I	NOUN	I
services	I-I	NOUN	I
by	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
chronic	I-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
.	I-P	PUNCT	O


No	O	DET	B
overall	O	ADJ	I
trend	O	NOUN	O
for	O	ADP	O
lower	O	ADJ	B
RU	B-OUT	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
sibenadet	O	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
correlates	O	VERB	O
with	O	ADP	O
the	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
sustained	O	ADJ	O
clinical	O	ADJ	B
effect	O	NOUN	I
seen	O	VERB	O
in	O	ADP	O
studies	O	NOUN	B
conducted	O	VERB	O
concurrently	O	ADV	O
.	O	PUNCT	O


Physicians	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
source	O	NOUN	B
of	O	ADP	O
care	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
COPD	O	NOUN	B
and	O	CCONJ	O
more	O	ADJ	O
of	O	ADP	O
the	O	DET	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
COPD	I-P	NOUN	B
(	I-P	PUNCT	O
stage	I-P	NOUN	B
III	I-P	NUM	I
)	I-P	PUNCT	O
than	I-P	ADP	O
mild	I-P	ADJ	B
(	I-P	PUNCT	O
stage	I-P	NOUN	B
I	I-P	NUM	I
)	I-P	PUNCT	O
were	O	AUX	O
seen	O	VERB	O
to	O	PART	O
utilize	O	VERB	O
the	O	DET	O
most	O	ADV	O
expensive	O	ADJ	B
resources	O	NOUN	B
(	O	PUNCT	O
e.g	O	INTJ	O
.	O	PUNCT	O


Beliefs	B-I	NOUN	B
underlying	O	VERB	O
the	O	DET	O
intention	O	NOUN	B
to	O	PART	O
donate	O	VERB	O
again	O	ADV	O
among	O	ADP	O
first-time	B-P	ADJ	B
blood	I-P	NOUN	B
donors	I-P	NOUN	I
who	I-P	PRON	O
experience	I-P	VERB	O
a	I-P	DET	O
mild	I-P	ADJ	B
adverse	I-P	ADJ	B
event	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
provide	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
those	O	DET	O
messages	B-I	NOUN	B
that	O	PRON	O
could	O	AUX	O
be	O	AUX	O
communicated	O	VERB	O
via	O	ADP	O
the	O	DET	O
mass	O	NOUN	B
media	O	NOUN	I
or	O	CCONJ	O
in	O	ADP	O
targeted	O	VERB	B
communications	O	NOUN	I
to	O	PART	O
retain	O	VERB	O
first-time	B-P	ADJ	B
donors	I-P	NOUN	B
who	O	PRON	O
have	O	AUX	O
experienced	O	VERB	O
a	O	DET	O
mild	O	ADJ	B
vasovagal	O	ADJ	B
reaction	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Initial	O	ADJ	B
nuclear	B-I	ADJ	B
magnetic	I-I	ADJ	I
resonance	I-I	NOUN	I
tomography	I-I	NOUN	I
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	B-P	NOUN	B
course	I-P	NOUN	I
of	I-P	ADP	O
avascular	I-P	ADJ	B
femur	I-P	NOUN	I
head	I-P	NOUN	B
necrosis	I-P	NOUN	I
after	I-P	ADP	O
femoral	I-P	ADJ	B
core	I-P	NOUN	I
decompression	I-P	NOUN	I
]	I-P	PUNCT	O
.	I-P	PUNCT	O


Aminocaproic	B-I	ADJ	B
acid	I-I	NOUN	I
versus	O	CCONJ	O
prednisone	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
traumatic	B-P	ADJ	B
hyphema	I-P	NOUN	I
.	I-P	PUNCT	O


We	O	PRON	O
report	O	VERB	O
characteristics	O	NOUN	B
of	O	ADP	O
a	O	DET	O
representative	B-P	ADJ	O
sample	I-P	NOUN	B
(	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
2,324	I-P	NUM	O
)	I-P	PUNCT	O
of	I-P	ADP	O
beachgoers	I-P	NOUN	B
in	I-P	ADP	O
Southeastern	I-P	PROPN	B
New	I-P	PROPN	I
England	I-P	PROPN	I
during	I-P	ADP	O
the	I-P	DET	O
summer	I-P	NOUN	B
of	I-P	ADP	O
1995	I-P	NUM	O
.	I-P	PUNCT	O


Hyperbaric	B-I	NOUN	B
oxygen	I-I	NOUN	I
attenuation	O	NOUN	I
of	O	ADP	O
lipopolysaccharide-induced	B-P	ADJ	B
acute	I-P	ADJ	I
lung	I-P	NOUN	I
injury	I-P	NOUN	I
involves	O	VERB	O
heme	O	NOUN	B
oxygenase-1	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
sought	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
heme	O	NOUN	B
oxygenase-1	O	NOUN	I
(	O	PUNCT	O
HO-1	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
this	O	DET	O
HBO	O	NOUN	B
inhibition	O	NOUN	B
of	O	ADP	O
iNOS	O	NOUN	B
induction	O	NOUN	B
and	O	CCONJ	O
acute	O	ADJ	B
lung	O	NOUN	I
injury	O	NOUN	I
in	O	ADP	O
septic	O	ADJ	B
rat	B-P	NOUN	I
lungs	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
HBO	B-I	NOUN	B
pre-treatment	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
rats	B-P	NOUN	B
were	O	AUX	O
further	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
the	O	DET	O
following	O	VERB	O
subgroups	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
)	O	PUNCT	O
:	O	PUNCT	O
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
LPS	B-I	NOUN	B
injection	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
ii	I-I	X	O
)	I-I	PUNCT	O
normal	I-I	ADJ	B
saline	I-I	NOUN	I
(	I-I	PUNCT	O
N/S	I-I	NOUN	B
)	I-I	PUNCT	O
injection	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
iii	I-I	X	O
)	I-I	PUNCT	O
hemin	I-I	NOUN	B
(	I-I	PUNCT	O
a	I-I	DET	O
HO-1	I-I	NOUN	B
inducer	I-I	NOUN	B
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
LPS	I-I	NOUN	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
iv	I-I	X	O
)	I-I	PUNCT	O
hemin	I-I	NOUN	B
alone	I-I	ADV	O
,	I-I	PUNCT	O
(	I-I	PUNCT	O
v	I-I	X	O
)	I-I	PUNCT	O
tin	I-I	NOUN	O
protoporphyrin	I-I	NOUN	B
(	I-I	PUNCT	O
SnPP	I-I	NOUN	B
;	I-I	PUNCT	O
a	I-I	DET	O
HO-1	I-I	NOUN	B
inhibitor	I-I	NOUN	I
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
LPS	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
(	I-I	PUNCT	O
vi	I-I	X	O
)	I-I	PUNCT	O
SnPP	I-I	NOUN	B
alone	I-I	ADV	O
.	I-I	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
HBO	B-I	NOUN	B
attenuation	O	NOUN	B
of	O	ADP	O
iNOS	O	NOUN	B
expression	O	NOUN	B
involves	O	VERB	O
HO-1	O	NOUN	B
induction	O	NOUN	B
.	O	PUNCT	O


Occurrence	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
needed	I-OUT	VERB	O
days	I-OUT	NOUN	B
for	I-OUT	ADP	O
healing	I-OUT	NOUN	B
of	I-OUT	ADP	O
minor	I-OUT	ADJ	B
RAS	I-OUT	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
during	O	ADP	O
the	O	DET	O
two	O	NUM	O
phases	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
alpha-Linolenic	B-OUT	ADJ	B
acid	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	B
in	I-OUT	ADP	O
the	I-OUT	DET	O
plasma	I-OUT	NOUN	B
phospholipid	I-OUT	NOUN	O
fraction	I-OUT	NOUN	O
increased	I-OUT	VERB	B
significantly	O	ADV	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
during	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
phase	O	NOUN	O
to	O	PART	O
a	O	DET	O
similar	O	ADJ	O
extent	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
bone	B-P	NOUN	B
turnover	I-P	NOUN	B
in	I-P	ADP	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


Our	O	PRON	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
bone	B-OUT	NOUN	B
turnover	I-OUT	NOUN	B
and	O	CCONJ	O
bone	B-OUT	NOUN	B
mineral	I-OUT	ADJ	I
density	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
postmenopausal	B-P	ADJ	B
,	I-P	PUNCT	O
osteopenic	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


Women	B-P	NOUN	B
aged	I-P	ADJ	B
50	I-P	NUM	O
to	I-P	PART	O
80	I-P	NUM	O
years	I-P	NOUN	B
received	O	VERB	O
raloxifene	B-I	NOUN	B
for	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
then	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
continue	O	VERB	O
raloxifene	B-I	NOUN	B
(	I-P	PUNCT	O
group	I-P	NOUN	B
1	I-P	NUM	O
,	I-P	PUNCT	O
n=20	I-P	ADJ	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
group	I-P	NOUN	B
2	I-P	NUM	O
,	I-P	PUNCT	O
n=20	I-P	ADJ	O
)	I-P	PUNCT	O
for	I-P	ADP	O
a	I-P	DET	O
further	I-P	ADJ	O
96	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


Following	O	VERB	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
bone	B-OUT	NOUN	B
markers	I-OUT	NOUN	B
returned	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
levels	O	NOUN	B
(	O	PUNCT	O
by	O	ADP	O
120	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
bone	B-OUT	NOUN	B
turnover	I-OUT	NOUN	B
of	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
raloxifene	O	NOUN	B
was	O	AUX	O
lost	O	VERB	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
hydraulic	O	ADJ	B
circuit	O	NOUN	I
training	O	NOUN	O
on	O	ADP	O
cardiovascular	B-P	ADJ	B
function	I-P	NOUN	I
.	I-P	PUNCT	O


Following	O	VERB	O
training	O	NOUN	B
VO2max	B-OUT	NOUN	I
(	I-OUT	PUNCT	O
ml.kg-1	I-OUT	NOUN	B
min-1	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
all	O	DET	O
training	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
18.0	O	NUM	O
,	O	PUNCT	O
12.5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
11.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
cycle	O	NOUN	B
,	O	PUNCT	O
HCTsub	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
HCTmax	B-OUT	NOUN	B
groups	I-OUT	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
VO2max	B-OUT	NOUN	B
observed	O	VERB	B
in	O	ADP	O
the	O	DET	O
cycle	O	NOUN	B
group	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
recorded	O	VERB	O
by	O	ADP	O
the	O	DET	O
two	O	NUM	O
HCT	O	NOUN	B
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
maximal	O	ADJ	B
and	O	CCONJ	O
submaximal	O	ADJ	B
HCT	O	NOUN	B
programs	O	NOUN	I
can	O	AUX	O
elicit	O	VERB	O
improvements	O	NOUN	B
in	O	ADP	O
cardiovascular	B-OUT	ADJ	B
fitness	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


UNLABELLED	O	VERB	B
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
randomized	O	ADJ	B
crossover	O	NOUN	O
trial	O	NOUN	O
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
on	O	ADP	O
autonomic	O	ADJ	B
responses	O	NOUN	I
in	O	ADP	O
preterm	B-P	NOUN	B
infants	I-P	NOUN	I
of	I-P	ADP	O
longer	I-P	PROPN	B
Kangaroo	I-I	PROPN	B
Care	I-I	PROPN	I
(	I-P	PUNCT	O
30	I-P	NUM	O
minutes	I-P	NOUN	B
,	I-P	PUNCT	O
KC30	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-P	CCONJ	O
shorter	I-P	ADJ	B
KC	I-I	NOUN	B
(	I-P	PUNCT	O
15	I-P	NUM	O
minutes	I-P	NOUN	B
,	I-P	PUNCT	O
KC15	I-I	NOUN	B
)	I-I	PUNCT	O
before	I-P	ADP	O
and	I-P	CCONJ	O
throughout	I-P	ADP	O
heel	I-P	NOUN	B
stick	I-P	NOUN	I
compared	I-P	VERB	B
with	I-P	ADP	O
incubator	I-I	NOUN	B
care	I-I	NOUN	I
(	I-I	PUNCT	O
IC	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-P	PUNCT	O


HR	B-OUT	NOUN	B
changes	O	NOUN	B
from	O	ADP	O
Baseline	O	NOUN	B
to	O	ADP	O
Heel	O	PROPN	B
Stick	O	PROPN	I
were	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
in	O	ADP	O
KC30	O	NOUN	B
and	O	CCONJ	O
KC15	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
IC	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
more	O	ADJ	O
infants	O	NOUN	B
had	O	AUX	O
HR	B-OUT	NOUN	B
decrease	O	NOUN	B
in	O	ADP	O
IC	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
2	O	NUM	O
KC	O	NOUN	B
conditions	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
3	O	NUM	O
conditions	O	NOUN	B
,	O	PUNCT	O
LF/HF	B-OUT	NOUN	B
ratio	I-OUT	NOUN	I
decreased	O	VERB	B
from	O	ADP	O
Baseline	O	NOUN	B
to	O	ADP	O
Heel	O	PROPN	B
Stick	O	PROPN	I
and	O	CCONJ	O
increased	O	VERB	B
to	O	ADP	O
Recovery	O	PROPN	B
;	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
IC	B-I	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
KC	B-I	NOUN	B
conditions	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
support	O	VERB	O
that	O	SCONJ	O
KC	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
safe	O	ADJ	O
and	O	CCONJ	O
effective	O	ADJ	B
pain	O	NOUN	B
intervention	O	NOUN	I
in	O	ADP	O
the	O	DET	O
neonatal	O	ADJ	B
intensive	O	ADJ	B
care	O	NOUN	I
unit	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
average	B-OUT	ADJ	B
VAS	I-OUT	NOUN	B
was	O	AUX	O
clearly	O	ADV	O
lower	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
coablation	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
epidural	B-I	ADJ	B
injections	I-I	NOUN	I
.	O	PUNCT	O


From	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
we	O	PRON	O
believe	O	VERB	O
that	O	SCONJ	O
acupuncture	B-I	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
many	O	ADJ	O
treatments	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cancer	I-P	NOUN	B
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
prelinguistic	B-I	ADJ	B
communication	I-I	NOUN	B
interventions	I-I	NOUN	B
on	O	ADP	O
the	O	DET	O
acquisition	O	NOUN	B
of	O	ADP	O
spoken	O	VERB	B
communication	O	NOUN	B
in	O	ADP	O
preschoolers	B-P	NOUN	B
with	I-P	ADP	O
ASD	I-P	PROPN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
PECS	B-OUT	NOUN	B
was	I-OUT	AUX	O
more	I-OUT	ADV	O
successful	I-OUT	ADJ	O
than	I-OUT	ADP	O
RPMT	I-OUT	NOUN	B
in	I-OUT	ADP	O
increasing	I-OUT	VERB	B
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
nonimitative	I-OUT	ADJ	B
spoken	I-OUT	VERB	B
communication	I-OUT	NOUN	B
acts	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
different	I-OUT	ADJ	O
nonimitative	I-OUT	ADJ	B
words	I-OUT	NOUN	B
used	I-OUT	VERB	O
at	I-OUT	ADP	O
the	I-OUT	DET	O
posttreatment	I-OUT	NOUN	B
period	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Considering	O	VERB	O
growth	O	NOUN	B
over	O	ADP	O
all	O	DET	O
3	O	NUM	O
measurement	O	NOUN	B
periods	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
exploratory	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
growth	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
different	I-OUT	ADJ	O
nonimitative	I-OUT	ADJ	B
words	I-OUT	NOUN	B
was	I-OUT	AUX	O
faster	I-OUT	ADJ	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
PECS	I-OUT	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
RPMT	O	NOUN	B
group	O	NOUN	B
for	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
began	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
relatively	O	ADV	O
high	O	ADJ	O
object	O	NOUN	B
exploration	O	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
enamel	B-I	NOUN	B
preparation	I-I	NOUN	I
method	I-I	NOUN	I
on	O	ADP	O
in	O	X	B
vitro	O	X	I
marginal	B-OUT	ADJ	B
microleakage	I-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
flowable	O	ADJ	B
composite	O	NOUN	I
used	O	VERB	O
as	O	ADP	O
pit	O	NOUN	B
and	O	CCONJ	O
fissure	O	NOUN	B
sealant	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Thirty	B-P	NUM	O
premolars	I-P	NOUN	B
were	O	AUX	O
divided	O	VERB	O
into	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
I	O	NUM	B
-	O	PUNCT	O
high-speed	B-I	ADJ	B
handpiece	I-I	NOUN	I
+	I-I	CCONJ	O
37	I-I	NUM	O
%	I-I	NOUN	O
phosphoric	I-I	ADJ	B
acid	I-I	NOUN	I
;	I-I	PUNCT	O
II	O	NUM	B
-	O	PUNCT	O
Er	B-I	PROPN	B
:	I-I	PUNCT	O
YAG	I-I	NOUN	B
laser	I-I	NOUN	I
(	I-I	PUNCT	O
350	I-I	NUM	O
mJ	I-I	NOUN	O
,	I-I	PUNCT	O
4	I-I	NUM	O
Hz	I-I	NOUN	O
and	I-I	CCONJ	O
112	I-I	NUM	O
J/cm	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
+	I-I	CCONJ	O
37	I-I	NUM	O
%	I-I	NOUN	O
phosphoric	I-I	ADJ	B
acid	I-I	NOUN	I
;	I-I	PUNCT	O
and	O	CCONJ	O
III	O	NUM	B
-	O	PUNCT	O
Er	B-I	PROPN	B
:	I-I	PUNCT	O
YAG	I-I	NOUN	B
laser	I-I	NOUN	I
(	I-I	PUNCT	O
350	I-I	NUM	O
mJ	I-I	NOUN	O
,	I-I	PUNCT	O
4	I-I	NUM	O
Hz	I-I	NOUN	O
and	I-I	CCONJ	O
112	I-I	NUM	O
J/cm	I-I	NOUN	O
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
+	I-I	CCONJ	O
Er	I-I	INTJ	B
:	I-I	PUNCT	O
YAG	I-I	NOUN	B
laser	I-I	NOUN	I
(	I-I	PUNCT	O
80	I-I	NUM	O
mJ	I-I	NOUN	O
,	I-I	PUNCT	O
4	I-I	NUM	O
Hz	I-I	NOUN	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
25	I-I	NUM	O
mJ/cm	I-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
)	I-I	PUNCT	O
)	I-I	PUNCT	O
.	O	PUNCT	O


All	O	DET	O
cavities	B-P	NOUN	B
received	O	VERB	O
the	O	DET	O
same	O	ADJ	O
adhesive	O	ADJ	B
system	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
restored	O	VERB	B
with	O	ADP	O
flowable	O	ADJ	B
composite	O	NOUN	I
according	O	VERB	O
to	O	ADP	O
manufacturer	O	NOUN	B
's	O	PART	I
instructions	O	NOUN	I
.	O	PUNCT	O


Teeth	O	NOUN	B
were	O	AUX	O
submitted	O	VERB	O
to	O	PART	O
thermal	B-I	ADJ	B
cycling	I-I	NOUN	O
and	O	CCONJ	O
immersed	O	VERB	B
in	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
silver	B-I	ADJ	B
nitrate	I-I	NOUN	B
solutions	I-I	NOUN	I
for	O	ADP	O
8	O	NUM	O
h	O	NOUN	O
in	O	ADP	O
total	O	ADJ	O
darkness	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
slice	O	NOUN	B
was	O	AUX	O
immersed	O	VERB	O
into	O	ADP	O
photo	O	NOUN	B
developing	O	NOUN	I
solution	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
photographed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
microleakage	B-OUT	NOUN	B
was	I-OUT	AUX	O
scored	I-OUT	VERB	B
from	I-OUT	ADP	O
0	I-OUT	NUM	O
to	I-OUT	PART	O
7	I-OUT	NUM	O
,	O	PUNCT	O
by	O	ADP	O
three	O	NUM	O
calibrated	O	VERB	B
examiners	O	NOUN	B
.	O	PUNCT	O


Dexmedetomidine	B-I	NOUN	B
pretreatment	O	NOUN	B
alleviates	O	VERB	O
propofol	B-P	NOUN	B
injection	I-P	NOUN	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
propofol	B-I	NOUN	B
injection	O	NOUN	B
pain	O	NOUN	I
during	O	ADP	O
induction	O	NOUN	B
of	O	ADP	O
general	O	ADJ	B
anesthesia	O	NOUN	I
varies	O	VERB	O
from	O	ADP	O
28	O	NUM	O
%	O	NOUN	O
to	O	PART	O
90	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
surgical	I-P	ADJ	I
procedures	I-P	NOUN	I
were	I-P	AUX	O
randomly	I-P	ADV	O
allocated	I-P	VERB	O
into	I-P	ADP	O
seven	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
30	I-P	NUM	O
patients	I-P	NOUN	B
each	I-P	DET	O
.	I-P	PUNCT	O


The	B-OUT	DET	O
median	I-OUT	ADJ	B
pain	I-OUT	NOUN	I
score	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
with	I-OUT	ADP	O
pain	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
>	O	VERB	O
2	O	NUM	O
in	O	ADP	O
group	O	NOUN	B
VII	O	NOUN	B
were	O	AUX	O
both	O	CCONJ	O
significantly	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
I	O	NOUN	I
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.000	O	NUM	O
,	O	PUNCT	O
both	O	DET	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Pretreatment	O	NOUN	B
with	O	ADP	O
intravenous	B-I	ADJ	B
DEX	O	NOUN	O
1	O	NUM	O
g/kg	O	NOUN	O
5	O	NUM	O
min	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
injection	O	NOUN	B
of	O	ADP	O
long-chain	O	ADJ	B
triglyceride	O	NOUN	I
propofol	O	NOUN	B
is	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
pain	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
propofol	O	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
We	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
a	O	DET	O
low-tilt	B-I	ADJ	B
biphasic	I-I	ADJ	B
waveform	I-I	NOUN	I
for	O	ADP	O
defibrillation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
low-tilt	B-I	ADJ	B
waveform	I-I	NOUN	I
was	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
a	O	DET	O
conventional	B-I	ADJ	B
waveform	I-I	NOUN	B
of	O	ADP	O
equivalent	O	ADJ	O
duration	O	NOUN	B
and	O	CCONJ	O
voltage	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
AF	I-P	NOUN	B
.	I-P	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
persistent	I-P	ADJ	B
AF	I-P	NOUN	I
or	I-P	CCONJ	O
AF	I-P	NOUN	B
induced	I-P	VERB	B
during	I-P	ADP	O
a	I-P	DET	O
routine	I-P	ADJ	B
electrophysiology	I-P	NOUN	B
study	I-P	NOUN	I
(	I-P	PUNCT	O
EPS	I-P	NOUN	B
)	I-P	PUNCT	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
the	O	DET	O
low-tilt	B-I	ADJ	B
waveform	I-I	NOUN	I
or	O	CCONJ	O
a	O	DET	O
conventional	B-I	ADJ	B
waveform	I-I	NOUN	I
.	I-I	PUNCT	O


Shock	O	NOUN	B
success	O	NOUN	I
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
return	B-OUT	NOUN	B
of	I-OUT	ADP	I
sinus	I-OUT	NOUN	B
rhythm	I-OUT	NOUN	O
for	O	ADP	O
>	O	X	O
/=30	O	PUNCT	O
seconds	O	NOUN	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Of	O	ADP	O
57	B-P	NUM	O
patients	I-P	NOUN	B
for	I-P	ADP	O
whom	I-P	PRON	O
we	I-P	PRON	O
thought	I-P	VERB	O
an	I-P	DET	O
operative	I-P	ADJ	B
intervention	I-P	NOUN	I
was	I-P	AUX	O
necessary	I-P	ADJ	O
,	O	PUNCT	O
30	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
TURP	B-I	PROPN	B
and	O	CCONJ	O
24	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
the	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
PKRP	B-I	PROPN	B
.	I-I	PUNCT	O


Operation	B-OUT	NOUN	B
times	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
urethral	I-OUT	ADJ	B
catheterization	I-OUT	NOUN	I
times	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
preoperative	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
Hb	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
Htc	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
Na	I-OUT	NOUN	O
values	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
complications	O	NOUN	B
of	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
compared	O	VERB	B
.	O	PUNCT	O


RESULTS	O	NOUN	O
On	O	ADP	O
first	O	ADJ	O
month	O	NOUN	B
and	O	CCONJ	O
first	O	ADJ	O
year	O	NOUN	B
follow	O	VERB	B
up	O	ADP	I
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
statistical	B-OUT	ADJ	B
difference	I-OUT	NOUN	I
in	O	ADP	O
I-PSS	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
maximum	I-OUT	ADJ	B
flow	I-OUT	NOUN	I
rate	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
average	I-OUT	ADJ	B
flow	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
residual	I-OUT	ADJ	B
urine	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
size	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
prostate	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
Na	I-OUT	NOUN	B
level	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
TURP	O	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
operation	B-OUT	NOUN	B
times	I-OUT	NOUN	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
It	O	PRON	O
is	O	AUX	O
obvious	O	ADJ	O
that	O	SCONJ	O
PKRP	B-I	PROPN	B
is	O	AUX	O
as	O	ADV	O
efficient	O	ADJ	B
as	O	ADP	O
TURP	O	PROPN	B
and	O	CCONJ	O
it	O	PRON	O
has	O	AUX	O
a	O	DET	O
similar	O	ADJ	O
morbidity	O	NOUN	B
.	O	PUNCT	O


Differential	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
resistance	B-I	NOUN	B
training	I-I	NOUN	O
in	O	ADP	O
CHF	O	NOUN	B
according	O	VERB	O
to	O	PART	O
ACE	O	NOUN	B
genotype	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
ACE	O	NOUN	B
genotype	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
response	O	NOUN	B
to	O	ADP	O
11weeks	B-I	NOUN	O
of	I-I	ADP	O
resistance	I-I	NOUN	B
exercise	I-I	NOUN	B
training	I-I	NOUN	O
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
37	B-P	NUM	O
CHF	I-P	NOUN	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
New	I-P	PROPN	B
York	I-P	PROPN	I
Heart	I-P	PROPN	I
Association	I-P	PROPN	I
Functional	I-P	ADJ	O
Class=2.30.5	I-P	NOUN	O
;	I-P	PUNCT	O
left	I-P	VERB	B
ventricular	I-P	ADJ	I
ejection	I-P	NOUN	I
fraction	I-P	NOUN	I
287	I-P	NUM	O
%	I-P	NOUN	O
;	I-P	PUNCT	O
age	I-P	NOUN	B
6412years	I-P	NOUN	O
;	I-P	PUNCT	O
32:5	I-P	NOUN	O
male	I-P	NOUN	B
:	I-P	PUNCT	O
female	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
randomised	I-P	VERB	B
to	O	PART	O
either	B-I	CCONJ	O
resistance	I-I	NOUN	B
exercise	I-I	NOUN	B
(	O	PUNCT	O
n=19	O	ADJ	O
)	O	PUNCT	O
or	B-I	CCONJ	O
inactive	I-I	ADJ	B
control	I-I	NOUN	O
group	I-I	NOUN	O
(	O	PUNCT	O
n=18	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
acute	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
fluid	O	ADJ	B
intake	O	NOUN	B
on	O	ADP	O
urine	O	NOUN	B
specific	O	ADJ	O
gravity	O	NOUN	B
and	O	CCONJ	O
fluid	O	ADJ	B
retention	O	NOUN	B
in	O	ADP	O
a	B-P	DET	O
mildly	I-P	ADV	B
dehydrated	I-P	ADJ	O
state	I-P	NOUN	O
.	I-P	PUNCT	O


The	O	DET	O
day-to-day	O	ADJ	B
variability	O	NOUN	B
in	O	ADP	O
morning	O	NOUN	B
USG	O	PROPN	B
(	O	PUNCT	O
coefficient	O	NOUN	B
of	O	ADP	I
variation	O	NOUN	I
=	O	ADJ	O
0.2	O	NUM	O
	O	NOUN	O
0.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
was	O	AUX	O
low	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
responses	O	NOUN	B
to	O	PART	O
600	O	NUM	O
ml	O	NOUN	O
of	O	ADP	O
W	O	NOUN	O
ingestion	O	NOUN	B
were	O	AUX	O
repeatable	B-OUT	ADJ	O
.	I-OUT	PUNCT	O


Adjunctive	O	ADJ	B
perampanel	B-I	NOUN	O
for	O	ADP	O
refractory	O	ADJ	B
partial-onset	O	ADJ	B
seizures	O	NOUN	I
:	O	PUNCT	O
randomized	O	ADJ	B
phase	O	NOUN	I
III	O	NUM	I
study	O	NOUN	I
304	O	NUM	O
.	O	PUNCT	O


METHODS	O	NOUN	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
multicenter	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
trial	O	NOUN	I
(	O	PUNCT	O
ClinicalTrials.gov	O	NOUN	O
identifier	O	NOUN	O
:	O	PUNCT	O
NCT00699972	O	ADJ	O
)	O	PUNCT	O
.	B-P	PUNCT	O


Following	O	VERB	O
baseline	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
patients	O	NOUN	B
entered	O	VERB	O
a	O	DET	O
19-week	O	ADJ	O
double-blind	O	ADJ	B
phase	B-I	NOUN	O
:	I-I	PUNCT	O
6-week	I-I	ADJ	B
titration	I-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
mg/week	I-I	NOUN	B
increments	I-I	NOUN	B
to	I-I	PART	O
target	I-I	VERB	B
dose	I-I	NOUN	B
)	I-I	PUNCT	O
followed	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
13-week	I-I	NOUN	O
maintenance	I-I	NOUN	B
period	I-I	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
intent-to-treat	O	ADJ	B
population	O	NOUN	I
over	O	ADP	O
the	O	DET	O
double-blind	O	ADJ	B
phase	O	NOUN	B
,	O	PUNCT	O
the	B-OUT	DET	O
median	I-OUT	ADJ	B
percent	I-OUT	NOUN	O
change	I-OUT	NOUN	O
in	I-OUT	ADP	O
seizure	I-OUT	NOUN	B
frequency	I-OUT	NOUN	B
was	O	AUX	O
-21.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
-26.3	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
-34.5	O	NUM	O
%	O	NOUN	O
for	B-I	ADP	O
placebo	I-I	NOUN	B
and	I-I	CCONJ	O
perampanel	I-I	NOUN	B
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0261	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.0158	O	NUM	O
for	O	ADP	O
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
vs	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Fifty	O	NUM	O
percent	O	ADJ	O
responder	O	NOUN	B
rates	O	NOUN	B
during	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
period	O	NOUN	B
were	O	AUX	O
26.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
37.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
36.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
for	B-I	ADP	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
perampanel	I-I	NOUN	B
8	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
and	B-I	CCONJ	O
perampanel	I-I	NOUN	B
12	O	NUM	O
mg	O	NOUN	O
;	O	PUNCT	O
these	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
for	O	ADP	O
8	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0760	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0914	B-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Sixty-eight	B-P	NUM	O
(	I-P	PUNCT	O
17.5	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
discontinued	I-P	VERB	B
,	I-P	PUNCT	O
including	I-P	VERB	O
40	I-P	NUM	O
(	I-P	PUNCT	O
10.3	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
for	I-P	ADP	O
adverse	I-P	ADJ	B
events	I-P	NOUN	I
.	O	PUNCT	O


CLASSIFICATION	O	NOUN	B
OF	O	ADP	O
EVIDENCE	O	NOUN	B
This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
Class	O	NOUN	B
I	O	NUM	I
evidence	O	NOUN	B
that	O	SCONJ	O
once-daily	O	NOUN	B
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
doses	O	NOUN	B
of	O	ADP	O
adjunctive	B-I	ADJ	B
perampanel	I-I	NOUN	B
are	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
uncontrolled	O	ADJ	B
partial-onset	O	ADJ	B
seizures	O	NOUN	I
.	O	PUNCT	O
